



Rak v Sloveniji

Cancer in Slovenia

2021

letno poročilo
annual report

Rak v Sloveniji

Cancer in Slovenia

2017

Naslov *Title*

Rak v Sloveniji 2017 / Cancer in Slovenia 2017

Uredniški odbor *Editorial Board*

Vesna Zadnik, glavna urednica / editor-in-chief

Gorana Gašljević, Marko Hočevar, Urška Ivanuš, Katja Jarm, Vera Pompe-Kirn, Primož Strojani, Sonja Tomšič, Branko Zakotnik in Tina Žagar

Računalniška obdelava *EDP Analysis*

Nika Bric, Tina Žagar, Katarina Lokar in Miran Mlakar

Oblikovanje in priprava za tisk *Design and Typesetting*

Nika Bric

Tisk *Printing*

Koštomaj d.o.o.

Izdajatelj *Published by*

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia

Epidemiologija in register raka / Epidemiology and Cancer Registry

Register raka Republike Slovenije / Slovenian Cancer Registry

Naklada *Published in*

800 izvodov / 800 copies

Nasvet za citiranje *Recommended Reference*

Rak v Sloveniji 2017. Ljubljana: Onkološki inštitut Ljubljana,

Epidemiologija in register raka, Register raka Republike Slovenije, 2020.

Cancer in Slovenia 2017. Ljubljana: Institute of Oncology Ljubljana,

Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2020.

Osebe Registra raka Republike Slovenije *Staff of the Slovenian Cancer Registry*

Vesna Zadnik, vodja / head

Agata Čampa, Mojca Čolnik, Maruška Ferjančič, Andrej Kirn, Andrej Krašovec,

Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, Polona Rus, Darja Strle,

Laura Šenekar Zupanc, Frančiška Škrlec, Polona Škulj, Urška Tomšič, Boštjan Zavrtnik,

Brigita Zore, Nika Bric, Ana Mihor, Miran Mlakar, Katarina Lokar, Sonja Tomšič, Tina Žagar

Naslov *Correspondence to*

Register raka Republike Slovenije / Slovenian Cancer Registry

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana

Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija

Telefon / Phone: + 386 1 5879 450

E-pošta / E-mail: register@onko-i.si

Spletna stran / Web site:

<http://www.onko-i.si/rrs/> <http://www.slora.si/>

<http://www.onko-i.si/eng/crs/> <http://www.slora.si/en/>

Uvodnik	6
<i>Editorial</i>	7
Podatki	8
Viri podatkov	8
Obdelava podatkov	9
Kakovost podatkov	10
<i>Data</i>	12
Data Sources	12
Data Processing	13
Data Quality	14
Rak v Sloveniji	15
Osnovni podatki o raku v Sloveniji 2017	16
Starost bolnikov	16
Časovni trend	16
Najpogostejši raki	18
Trend najpogostejših rakov	21
Redki raki	22
Preživetje	23
Primerjava z Evropo	26
<i>Cancer in Slovenia</i>	28
Basic figures on cancer in Slovenia 2017	28
Age of patients	28
Time trends	29
Most frequent cancers	29
Time trends for most frequent cancers	29
Rare cancers	30
Survival	30
Comparisons with Europe	31
Incidenca <i>Incidence</i>	32
Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2008–2017 in 2020.	32
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2008–2017 and 2020.	32
Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2017.	33
Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2017.	33
Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2017.	34
Table 3: Cancer incidence by age and by sex with crude rate (CR) per 100,000 population and cumulative rate (CR), Slovenia 2017.	34

Tabela 4a:	Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2017.	38
Table 4a:	Incidence of microscopically (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2017.	38
Tabela 4b:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2017.	42
Table 4b:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2017.	42
Tabela 4c:	Incidenca ne-Hodgkinovih limfomov po lokaciji, Slovenija 2017.	43
Table 4c:	Incidence of non-Hodgkin's malignant lymphomas by cancer site, Slovenia 2017.	43
Tabela 5:	Incidenca raka po stadiju, Slovenija 2017.	44
Table 5:	Cancer incidence by stage, Slovenia 2017.	44

Prevalenca *Prevalence* 46

Tabela 6:	Prevalenca po spolu, Slovenija, 31. 12. 2017.	46
Table 6:	Prevalence of cancer patients by sex, Slovenia, December 31, 2017.	46

Umrljivost *Mortality* 47

Tabela 7:	Umrljivost za rakom po starosti in spolu, Slovenija 2017. Vir: Nacionalni inštitut za javno zdravje	47
Table 7:	Cancer mortality by age and by sex, Slovenia 2017. Source: National Institute of Public Health	47

Preživetje *Survival* 48

Tabela 8:	Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2013–2017.	48
Table 8:	One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2013–2017 by sex.	48

Zdravljenje *Treatment* 49

Tabela 9a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL).	49
Table 9a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given).	49
Tabela 9b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani*, po bolnici posega.	50
Table 9b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery during their first treatment* by treatment institution.	50
Tabela 9c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po bolnici zdravljenja.	51
Table 9c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by systemic therapy during their first treatment* by treatment institution.	51

Breme najpogostejših rakov <i>Cancer Fact Sheets</i>	52
Vsi raki / All cancer sites (C00–C96)	52
Prostata / Prostate (C61)	53
Pljuča in sapnik / Lung and trachea (C33, C34)	54
Dojka / Breast (C50)	55
Debelo črevo in danka / Colon and rectum (C18–C20)	56
Koža, razen melanoma / Skin, non-melanoma (C44)	57
Kožni melanom / Malignant melanoma of skin (C43)	58
Glava in vrat / Head and neck (C00–C14, C30–C32)	59
Maternično telo / Corpus uteri (C54)	60
Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)	61
Pojmovnik	62
<i>Glossary</i>	63

Uvodnik

Register raka Republike Slovenije je v svetovnem merilu prepoznan kot eden najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od začetka deluje v okviru Onkološkega inštituta Ljubljana. Začetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporočili Svetovne zdravstvene organizacije zavedala, da je uspešnost in učinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoče objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v času. Letos praznujemo 70. letnico neprekinjenega delovanja slovenskega Registra raka. Častitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani www.onko-i.si/rrs ter v posebej za to priložnost izdani brošuri.

Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje Državnega programa obvladovanja raka na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti). Dragoceni so za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov. Z natančnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru kliničnih registrov, pa lahko, poleg zgoraj opisanega, spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišničnega registra Onkološkega inštituta Ljubljana, ki že ves čas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogočajo podrobnejši pregled nad bolniki, zdravljenimi na Inštitutu.

Redna letna poročila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben čas za izdajo letnega poročila nekoliko daljši, v poročilih zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2020). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga poimenovali SLORA po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoča primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in svetu.

Vsem, ki so kakorkoli prispevali k izdaji tega poročila, tako sodelavcem Registra raka, kot tudi vsem zdravnikom in kliničnemu osebju po vsej državi, ki ste nam posredovali poročila o diagnozi in zdravljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem.



prof. dr. Vesna Zadnik, dr. med.
vodja Registra raka Republike Slovenije

Ljubljana, september 2020

The Slovenian Cancer Registry is recognized as one of the oldest and best quality population-based cancer registries in Europe and the world. Founded in 1950, from the very beginning it has operated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, Prof Dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. This year we are celebrating the 70th anniversary of continuous operation at the Slovenian Cancer Registry. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Register in all these years. Readers interested in learning more can find historical facts and anecdotes on our website www.onko-i.si/rrs and in a brochure published especially for this occasion.

Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, together with mortality data collected and processed by the National Institute of Public Health, are the basis for assessing the burden of cancer in the country. The Registry's data are important for the planning and evaluation of the National Cancer Control Programme for primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as in planning regarding facilities and resources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research, and for evaluating the effectiveness of screening programmes. In addition to all this, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment oncology patients receive. Data of the Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nation-wide Cancer Registry and in large part also supplied with data via the Registry, provides a more detailed overview of patients treated at the Institute.

Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional community and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, in recent years we have started to include in the report the projected cancer incidence for the year when the report is issued (i.e. for 2020 in this report). Since 2010, our SLORA interactive web portal – www.slora.si – has also been up and running; it is named based on the initial letters of the words »Slovenija and cancer [rak]«. It provides easy and quick access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of the cancer burden in Slovenia with other countries in Europe and the world.

On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff at the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment.




prof. Vesna Zadnik, MD, PhD
director of the Slovenian Cancer Registry

Ljubljana, September 2020

Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vključevanjem različnih virov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju različnih zbirk se uporablja enotni državni identifikator EMŠO.



Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravijo in spremljajo. Tradicionalno bolnišnice poročajo Registru raka na posebnem formularju *Prijavnici rakave bolezni*. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Kliniki Golnik zbirajo podatke za *Prijavnico* v lastnem bolnišničnem registru ter jih v Register raka od tam posredujejo elektronsko; v ostalih bolnišnicah *Prijavnice* izpolnjujejo zdravniki, ki bolnika obravnavajo ali od njih pooblaščen osebje. Skladno s cilji Državnega programa obvladovanja raka 2017-2021 smo v letu 2019 začeli uvajati tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Registru raka posredujejo seznam bolnikov ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno poročanje prek *Prijavnic* je tako ukinjeno. Za zbolele v letu 2017, ki so prikazani v tem poročilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem kliničnem centru Maribor, Pediatrični kliniki ter Kliničnem oddelku za hematologijo Univerzitetnega kliničnega centra Ljubljana.

Dopolnilni vir podatkov Registra raka so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojke in Svit za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne analize

prostorske razporeditve raka nam omogoča točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi prebivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi začasem, kot je upoštevano v pripravi števila prebivalcev po klasični »statistični« definiciji.

Pri izračunavanju in interpretiranju večine kazalnikov bremena raka so poleg podatkov o bolnikih ključni tudi nacionalni podatki o številu prebivalcev in o njihovi starostni strukturi. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2017 so prikazani v tabeli.

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2017.
Population of Slovenia by age and sex on July 1st 2017.

Starostna skupina Age group	Skupaj All	Moški Males	Ženske Females
0-4	104641	53807	50834
5-9	110822	57050	53772
10-14	94223	48408	45815
15-19	92875	48074	44801
20-24	101880	52496	49384
25-29	120713	62660	58053
30-34	139091	72723	66368
35-39	156318	82397	73921
40-44	153308	80000	73308
45-49	145866	75223	70643
50-54	155103	78618	76485
55-59	148609	74783	73826
60-64	147083	73577	73506
65-69	123777	59943	63834
70-74	87383	39379	48004
75-79	77709	32646	45063
80-84	57714	21012	36702
85+	49046	13177	35869
Skupaj / Total	2066161	1025973	1040188

Obdelava podatkov

Podatke, prispel v Register raka posebej usposobljene medicinske sestre v procesu registracije kodirajo v skladu z mednarodnimi in v registru dogovorjenimi pravili.

Lokacija tumorja

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Morfologija tumorja

Pri uvrščanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011).

Stadij bolezni

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer bolezni, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1).

V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu beležimo tudi velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov


V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima indirektnima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli.

Incidenca raka glede na način postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2017.
Cancer incidence according to basis of diagnosis, Slovenia 2017.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only		
			Število Number	%	Število Number	%	Število Number	%	
C00–C96	Vse lokacije All sites	Moški in ženske / Males and females	14987	14276	95,3	670	4,5	41	0,3
		Moški / Males	7974	7597	95,3	360	4,5	17	0,2
		Ženske / Females	7013	6679	95,2	310	4,4	24	0,3
C00–C14	Usta in žrelo / Mouth and pharynx	350	349	99,7	1	0,3	0	0,0	
C15	Požiralnik / Oesophagus	88	83	94,3	5	5,7	0	0,0	
C16	Želodec / Stomach	425	413	97,2	10	2,4	2	0,5	
C18	Debelo črevo / Colon	783	765	97,7	17	2,2	1	0,1	
C19–C20	Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction	538	524	97,4	12	2,2	2	0,4	
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	262	150	57,3	110	42,0	2	0,8	
C23–C24	Žolčnik in žolčevodi / Gallbladder and biliary tract	195	135	69,2	59	30,3	1	0,5	
C25	Trebušna slinavka / Pancreas	410	270	65,9	136	33,2	4	1,0	
C32	Grlo / Larynx	94	94	100,0	0	0,0	0	0,0	
C33–C34	Sapnik, sapnici in pljuča / Trachea, bronchus and lung	1457	1359	93,3	92	6,3	6	0,4	
C43	Maligni melanom kože / Malignant melanoma of skin	578	578	100,0	0	0,0	0	0,0	
C44	Druge maligne neoplazme kože / Skin, other malignomas	3156	3147	99,7	9	0,3	0	0,0	
C48–C49	Vezivno in mehko tkivo / Connective and soft tissue	71	71	100,0	0	0,0	0	0,0	
C50	Dojka / Breast	1409	1398	99,2	5	0,4	6	0,4	
C53	Maternični vrat / Cervix uteri	86	85	98,8	1	1,2	0	0,0	
C54	Maternično telo / Corpus uteri	351	349	99,4	1	0,3	1	0,3	
C56	Jajčnik / Ovary	157	147	93,6	10	6,4	0	0,0	
C61	Prostata / Prostate	1595	1545	96,9	45	2,8	5	0,3	
C62	Modo / Testis	125	125	100,0	0	0,0	0	0,0	
C64–C65	Ledvica z ledvičnim mehom / Kidney with renal pelvis	403	362	89,8	40	9,9	1	0,2	
C67	Sečni mehur / Bladder	357	351	98,3	5	1,4	1	0,3	
C70–C72	Centralni in avtonomni živčni sistem / Central and autonomic nervous system	201	174	86,6	27	13,4	0	0,0	
C73	Ščitnica / Thyroid gland	211	211	100,0	0	0,0	0	0,0	
C81	Hodgkinova limfom / Hodgkin's lymphoma	57	57	100,0	0	0,0	0	0,0	
C82–C85	Ne-Hodgkinovi limfomi / Non-Hodgkin's lymphoma	390	390	100,0	0	0,0	0	0,0	
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	141	141	100,0	0	0,0	0	0,0	
C91–C95	Levkemije / Leukaemias	329	329	100,0	0	0,0	0	0,0	

Data Sources

Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases.



The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via a special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registers collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals the Notification forms are filled in by the treating physicians or by the staff who they authorize. In accordance with the goals of the National Cancer Control Program for 2017-2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting through Notification Forms will gradually be phased out. For patients diagnosed in 2017, data on whom are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana.

Complementary sources of information for the Cancer Registry are death certificates that we get from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of precancerous and

early cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for the detection of precancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient's vital status (whether the person is alive, dead or lost to follow-up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accurately defined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis, and not the temporary one, contrary to the standard "statistical" definition of the population used for calculating the number of inhabitants.

In addition to patient data, national population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. The census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In Annual Reports the population data on July 1 of a particular year are used, which are obtained from the SI-STAT Data Portal of the Statistical Office of the Republic of Slovenia. In the table on page 9, numbers of inhabitants of Slovenia in 2017 by age and sex are presented.

Data Processing

In the Cancer Registry, specially trained nurses code the data retrieved from notifications of cancer in accordance with international and internal Registry guidelines for cancer registration.

Tumour Location

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8th revision was used (ICD-8).

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well.

Tumour Morphology

When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the third edition has been in use, including the 2011 updates. In this edition some changes were introduced in terms of morphology and behaviour coding and some new morphology codes were added for tumours that before 2001 were not coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two

being assigned to C96.7, while the polycythaemia is classified under the topography code C94 from year 2001 on.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a greater number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification.

Cancer Staging

For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumour is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours only T1 tumour is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the distant stage (M1).

Stage according to TNM or any other appropriate classification is also stored in the Cancer Registry database, if available. Additionally, FIGO classification is used for gynaecological tumours, size according to Clark's level and Breslow's thickness in skin melanoma, and Ann-Arbor System for malignant lymphomas.

Data Quality


The quality of information can be directly assessed by the following standard internationally harmonized parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in table on page 11.

Rak v Sloveniji

Za dodatne podatke o bremenu raka v Sloveniji in svetu obiščite: www.slora.si.

- Od rojenih leta 2017 bosta do svojega 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk.
- Za rakom zboli letno okrog 15.000 Slovencev, skoraj 8.000 moških in več kot 7.000 žensk, umre pa jih več kot 6.000, približno 3.500 moških in 2.800 žensk; med nami živi že več kot 100.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca).
- Kljub temu, da se ogroženost z rakom zmeroma večja, je največja pri starejših; od vseh rakavih bolnikov, zbolelih leta 2017, jih je bilo več kot 60 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.
- Najpogostejši raki pri nas (kože, prostate, debelega črevesa in danke, pljuč, pa tudi dojke) so leta 2017 predstavljali 60 % vseh ugotovljeni rakov. Povezani so z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač; ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Presejalni programi za rake, ki jih priporoča Svet Evropske zveze (EZ) in smo jih uvedli tudi v Sloveniji, bodo z zgodnjim odkrivanjem zmanjšali umrljivost za rakom dojk, debelega črevesa in danke ter rakom materničnega vratu; pri slednjih dveh bodo zmanjšali tudi incidenco.
- Petletno čisto preživetje odraslih slovenskih bolnikov s katero koli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2013–2017, je bilo 57 %, bolnic pa 60 %.

Povzetek




Slika 1. Breme raka, Slovenija 2017.
Figure 1. Cancer burden, Slovenia 2017.

Osnovni podatki o raku v Sloveniji 2017

- Leta 2017 je v Sloveniji za rakom zbolelo 14.987 ljudi (7.974 moških in 7.013 žensk).
- Starostno standardizirana incidenčna stopnja (evropsko prebivalstvo) je bila 484,9/100.000; 563,9 pri moških in 430,3 pri ženskah. Od rojenih leta 2017 bosta do svojega 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk.
- Leta 2017 je za rakom umrlo 6.365 Slovencev, 3.570 moških in 2.795 žensk. Med nami je živel 111.696 ljudi (50.941 moških in 60.755 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca).
- Med posameznih slovenskih regijah ne opažamo bistvenih razlik v bremenu raka.

Starost bolnikov


- Čeprav se ogroženost z rakom zmeroma večja, je največja v poznejših letih; od vseh rakavih bolnikov je leta 2017 kar 64 % moških in 60 % žensk zbolelo po dopolnjeni starosti 65 let. Manj kot odstotek vseh rakavih bolezni je ugotovljenih pri otrocih in mladostnikih (do 20. leta).
- Ker se slovensko prebivalstvo stara, je samo zaradi čedalje večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo. Ocenjujemo, da je bilo leta 2020 že 15.800 novih bolnikov.




Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2017.
Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2017.

Časovni trend

- V splošnem se groba incidenčna in umrljivostna stopnja raka večata.
- Groba incidenčna stopnja se je v zadnjih dvajsetih letih skoraj podvojila, v zadnjem desetletju se večja za 2 % povprečno letno (1,9 % pri moških in 2,1 % pri ženskah). Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih večala povprečno za 1,0 % letno, pri ženskah pa za 0,8 %.
- Več kot polovica tega povečanja gre pripisati staranju prebivalstva, saj ima z daljšo življenjsko dobo tudi več ljudi možnost dočakati to bolezen. Starostno standardizirana, kumulativna incidenčna stopnja kaže, da se tveganje raka večja počasneje, pri moških se trend celo obrača navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (če ne upoštevamo staranja) manjša, predvsem od sredine devetdesetih let, kar kaže na večjo uspešnost zdravljenja.




Slika 3. Groba letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2017.
Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2017.




Slika 4. Kumulativna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo v zadnjih 10 letih, Slovenija 1950–2017.
Figure 4. Cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2017.

Najpogostejši raki

- Rak ni ena sama bolezen, temveč več sto različnih. Te lahko vzniknejo v vseh tkivih in organih človeškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi različne bolj ali manj znane nevarnostne dejavnike.
- Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), prostate, raki debelega črevesa in danke, dojke in pljuč obsegajo 60 % vseh novih primerov rakavih bolezni.
- Najpogostejši raki so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Pri moških je bil z 20 % vseh rakov na prvem mestu rak prostate, sledili so mu kožni rak (brez melanoma), pljučni rak in rak debelega črevesa in danke. Pri ženskah zavzemata nemelanomski kožni rak in rak dojke vsak po petino vseh rakov, sledijo pljučni rak ter debelega črevesa in danke.
- Najpogostejši raki so v raznih življenjskih obdobjih različni. Pri otrocih in mladostnikih do 20. so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živčnega sistema. Mlajši odrasli moški zbolevajo največ za rakom mod, pri ženskah v tej starosti pa je na prvem mestu že rak dojke.



Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2017.
Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2017.



*Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00-C14, C30-C32)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33-C34)


Debelo črevo in danka / Colorectum (C18-C20)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64-C65)

Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2017.
Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2017.


Ženske Females

Povprečna letna incidenca



Moški Males

Average annual incidence



*Pojasnilo / Explanation:

Debelo črevo in danka / Colorectum (C18–C20)
 Trebušna slinavka / Pancreas (C25)
 Pljuča / Lung (C33–C34)
 Kosti / Bone (C40–C41)
 Koža, melanom / Skin, melanoma (C43)
 Koža, razen melanoma / Skin, non-melanoma (C44)
 Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)
 Glava in vrat / Head and neck (C00–C14, C30–C32)


Dojka / Breast (C50)
 Maternični vrat / Cervix uteri (C53)
 Maternično telo / Corpus uteri (C54)
 Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)
 Ščitnica / Thyroid gland (C73)
 Hodgkinov limfom / Hodgkin's disease (C81)
 Levkemije / Leukaemias (C91–C95)

Želodec / Stomach (C16)
 Prostata / Prostate (C61)
 Modo / Testis (C62)
 Ledvica z ledvičnim meh. / Kidney with renal pelvis (C64–C65)
 Sečni mehur / Bladder (C67)
 Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin's lymphoma (NHL) (C82–C85)

Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2013–2017.
 Figure 6: Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2013–2017.


Trend najpogostejših rakov

- Med pogostejšimi rakavimi boleznimi se je pri moških incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000.
- Strmo pa pljučnega raka prehitevata rak prostate (povečanje za povprečno 2,0 % na leto) in kožni nemelanomski rak (povečanje za povprečno 5,3 % na leto). Izjemno povečanje incidence raka prostate v prejšnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno že dosegli.
- Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (SVIT). Incidenca raka debelega črevesa in danke se je pri moških med leti 2008 in 2010 povečevala za 8,2 % letno, od leta 2010 do 2017 pa pada za 3,7 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7.
- Med pogostejšimi rakavimi boleznimi so se pri ženskah večale incidenčne stopnje raka dojke (za 2,0 % povprečno letno), kože, razen melanoma (povečanje za 4,3 % povprečno letno), pljučnega raka (za 5,9 % povprečno letno) in raka materničnega telesa (za 2,8 % povprečno letno).
- Incidenčna stopnja raka materničnega vratu od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo pada (za povprečno 3,5 % na leto v zadnjih desetih letih).
- Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa SVIT leta 2009 spreminja časovni trend pojavljanja raka debelega črevesa in danke – od leta 2008 pada incidenca raka debelega črevesa in danke za povprečno 2,3 % na leto.



Slika 7a. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2017.

Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in males, Slovenia 1950–2017.




Slika 7b. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2017.

Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in females, Slovenia 1950–2017.

Redki raki

- Poseben izziv državam so redke rakave bolezni (opredeljene kot tiste, ki jih je letno manj kot 6 novih primerov na 100.000 prebivalcev).
- Skupaj so redki raki v Sloveniji predstavljali približno petino od vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo okrog 3.000 bolnikov.
- Za redke rake je značilno, da se v primerjavi s pogostejšimi večkrat pojavljajo pri otrocih in mladostnikih.
- Kot pri vseh redkih boleznih so tudi pri redkih rakih težave podobne: pozno in težko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni dostopno. Da bi uspešno obvladovali redke rake je pomembno, da njihovo breme natančno spremljamo, ter da vse države sprejmejo smernice in določijo referenčne centre za diagnostiko in zdravljenje teh bolnikov.




Preživetje

- Petletno čisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2013–2017, je bilo že 56,7 %, pri ženskah pa je preseglo 60 %.
- Več kot 80 % je bilo čisto 5-letno preživetje pri moških z rakom mod, ščitnice, Hodgkinovo boleznijo, rakom prostate in kožnim melanomom. Pri ženskah pa pri bolnicah z rakom ščitnice, kožnim melanomom, Hodgkinovo boleznijo, rakom dojke in rakom materničnega telesa.
- V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov zbolelih med leti 1997 in 2016. Rezultati analize so na voljo v publikaciji Zadnik V, Žagar T, Lokar K, Tomšič S, Duratović Konjević A, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji, ki je dostopna v pdf obliki tudi na www.onko-i.si/rrs. Glavni zaključki so:


1. Preživetje slovenskih bolnikov z rakom se s časom povečuje. V zadnjih 20. letih (1997-2001 in 2012-2016) se je petletno čisto preživetje povečalo za 11 odstotnih točk. Občutno večja je rast pri moških kjer se je petletno čisto preživetje povečalo za 17 odstotnih točk (iz 38 % na 55 %). Pri ženskah je petletno čisto preživetje zraslo za 6 odstotnih točk (iz 54 % na 60 %).
2. Ključna za preživetje bolnikov z rakom sta še vedno starost in stadij ob diagnozi. Petletno čisto preživetje je najmanjše pri starejših od 75 let, se je pa tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih točk. Petletno čisto preživetje bolnikov z omejenim stadijem se je v 20. letih povečalo za 10 odstotnih točk; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje.
3. Pri obeh spolih so se v zadnjih 20. letih značilno povečala preživetja pri treh pogostih rakih: raku na debelem črevesu in danki (za 14 odstotnih točk iz 48 % na 62 %), kožnem melanomu (za 12 odstotnih točk iz 79 % na 91 %) ter pri pljučnem raku (za 8 odstotnih točk iz 10 % na 18 %). Rezultat odraža zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju.
4. Občuten je tudi napredek pri obeh najpogostejših rakih, raku dojke pri ženskah in raku prostate pri moških: petletno čisto preživetje bolnic z rakom dojke se je v zadnjih 20. letih povečalo za 10 odstotnih točk, petletno čisto preživetje bolnikov z rakom prostate pa celo za več kot 20 odstotnih točk. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekritično uporabljali testiranje PSA s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinično nemi ter tako, s predhodno diagnozo, umetno podaljšali preživetja.
5. V skupino rakov, kjer napredka s časom ni opaziti ter pri katerih preživetja še vedno ostajajo slaba, pa sodijo rak trebušne slinavke, rak požiralnika, raki jeter, žolčnika in žolčevodov ter možganski tumorji.
6. V raziskavi CONCORD-3 smo primerjali petletna čista preživetja odraslih bolnikov s petnajstimi različnimi vrstami raka zbolelimi med leti 2010 in 2014 v 26. evropskih državah. Preživetja slovenskih bolnikov z rakom so v večini primerov pod evropskim povprečjem, kar nam daje dobro osnovo za nadaljnje izboljšave.
7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zboleljajo predvsem za levkemijami, tumorji osrednjega živčevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997-2001 in 2012-2016) se je petletno preživetje otrok in mladostnikov zbolelih za rakom povečalo za 7 odstotnih točk (iz 79 % na 86 %).

Moški Males



Slika 9a. Petletno čisto preživetje (s 95 % intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2013-2017 in 2008-2012.

Figure 9a. Five-year net survival (with 95% confidence interval) for males diagnosed with selected cancers in periods 2013-2017 and 2008-2012.



Slika 9b. Petletno čisto preživetje (s 95 % intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2013-2017 in 2008-2012.


Figure 9b. Five-year net survival (with 95% confidence interval) for females diagnosed with selected cancers in periods 2013-2017 and 2008-2012.

Primerjava z Evropo

- Kot je ocenjeno v okviru Evropskega informacijskega sistema za raka (<https://ecis.jrc.ec.europa.eu/>), je bila Slovenija leta 2020 po incidenčni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (616/100.000) na osmem mestu med 27 evropskimi državami. Višjo incidenco so imele Irska, Danska, Nizozemska, Belgija, Ciper, Madžarska in Francija.
- Po umrljivostni stopnji smo na sedmem mestu, pred nami so Slovaška, Poljska, Ciper, Madžarska, Hrvaška in Danska.

Ocena incidence po državah Estimated incidence by country


EU-27, vse lokacije brez nemelanomskega kožnega, vse starosti, oba spola 2020
EU-27, all sites but non-melanoma skin, all ages, both sexes, 2020



Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidenčna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020.
Figure 10a. Estimated age standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2020.

Ocena umrljivosti po državah Estimated mortality by country

EU-27, vse lokacije brez nemelanomskega kožnega, vse starosti, oba spola 2020
EU-27, all sites but non-melanoma skin, all ages, both sexes, 2020



Starostno standardizirana stopnja na 100.000
Age standardized rate (European new) per 100.000

Vir: ECIS - Evropski informacijski sistem za raka
<https://ecis.jcr.ec.europa.eu>
Source: ECIS - European Cancer Information System

Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020.
Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2020.

Cancer in Slovenia

For additional information on the burden of cancer in Slovenia and the world, visit: www.slora.si.
Figures are available on pages 15–27.

Summary

- Among those born in 2017, one in two men and one in three women are expected to develop cancer by the age of 75.
- Every year, around 15,000 Slovenians (almost 8,000 men and more than 7,000 women) are diagnosed with cancer, and more than 6,000 (about 3,500 men and 2,800 women) die of cancer. Currently, there are already over 100,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence).
- The risk of developing cancer increases gradually with age and is highest among the older population; of all cancer patients diagnosed in 2017, more than 60% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of older people.
- In 2017, the most frequent cancers in Slovenia (skin, prostate, colorectal, lung, and breast) accounted for 60% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption – primary prevention measures should be in place with the aim to reduce their burden.
- Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia are expected to lower mortality from breast, colorectal and cervical cancer through early detection; for colorectal and cervical cancer, a reduction in cancer incidence is also expected.
- The five-year net survival of adult Slovenian patients with any type of cancer (excluding non-melanoma skin cancer) who were diagnosed in the 2013–2017 period was 57% in men and 60% in women.

Basic figures on cancer in Slovenia 2017

- In 2017, 14,987 people (7,974 men and 7,013 women) were diagnosed with cancer in Slovenia.
- The age-standardized incidence rate (European standard population) was 484.9/100,000; 563.9 in men and 430.3 in women. Among those born in 2017, one in two men and one in three women are expected to develop cancer by the age of 75.
- In 2017, 6,365 Slovenians died of cancer, 3,570 men and 2,795 women. There were 111,696 people alive in Slovenia (50,941 men and 60,755 women) who had at some point during their lifetime been diagnosed with cancer (prevalence).
- There are no significant differences in the burden of cancer between regions of Slovenia.

Age of patients

- Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2017, as many as 64% men and 60% women were diagnosed with cancer after the age of 65. Less than one percent of all cancers were diagnosed in children and adolescents (up to 20 years of age).

- As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of older people. We estimate that in 2020, there were as many as 15,800 newly diagnosed cancer patients.

Time trends

- In general, the crude incidence and mortality rates of cancer are increasing.
- The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 2% per year over the last decade (by 1.9% in men and 2.1% in women). The crude mortality rate has increased on average by 1.0% per year in men over the last 10 years, and by 0.8% in women.
- More than half of this increase can be attributed to an ageing population, as longer life expectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend even reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment.

Most frequent cancers

- Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment, and outcome, and are also associated with different, more or less established risk factors.
- The five most frequent cancers in Slovenia – skin (excluding melanoma), prostate, colorectal, breast and lung – account for 60% of all new cancer cases.
- The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden.
- In men, prostate cancer was most frequent, accounting for 20% of all cancers, followed by skin cancer (excluding melanoma), lung cancer, and colorectal cancer. In women, non-melanoma skin cancer and breast cancer each account for one-fifth of all cancers, followed by lung cancer and colorectal cancer.
- The most frequent cancers differ according to age. In children and adolescents aged up to 20 years, leukaemias are most frequent, followed by tumours of the central and autonomic nervous system. Young adult men are most often diagnosed with testicular cancer, while in young women, breast cancer is already ranked first.

Time trends for most frequent cancers

- Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 1990s, when it stabilized at around 90/100,000.
- Lung cancer is outranked by the steep rising rates of prostate cancer (an increase of 2.0% per year on average) and non-melanoma skin cancer (an increase of 5.3% on average per year). The dramatic increase in the incidence of prostate cancer over the past decade is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years indicate that we have already

reached the peak incidence of prostate cancer.

- Time trends in the incidence of colorectal cancer must also be interpreted by taking into account changes in diagnostics – in 2009 Slovenia introduced the national screening and early detection programme for colorectal cancer (Svit). The incidence of colorectal cancer in men increased by 8.2% per year between 2008 and 2010, and decreased by 3.7% per year from 2010 to 2017. Average annual percentage changes are shown next to the incidence curves in Figure 7.
- Among the more frequent cancers in women, incidence rates have been increasing for breast cancer (by 2.0% on average per year), skin, excluding melanoma (by 4.3% on average per year), lung cancer (by 5.9% on average per year) and uterine cancer (by 2.8% on average per year).
- The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 3.5% per year in the last ten years).
- Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – since 2008 the incidence of colorectal cancer has been declining by an average of 2.3% per year.

Rare cancers

- A particular challenge for countries are rare cancers (defined as those with less than six new cases per 100,000 per year).
- In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year.
- As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents.
- Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for the diagnostics and treatment of such patients.

Survival

- The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2013 and 2017 was 56.7%, while in women it was over 60%.
- The five-year net survival was over 80% in men with testicular cancer, thyroid cancer, Hodgkin's disease, prostate cancer, and skin melanoma, and in women with thyroid cancer, skin melanoma, Hodgkin's disease, breast cancer and uterine cancer.
- In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication Zadnik V, Žagar T, Lokar K, Tomšič S, Duratović Konjević A, Zakotnik B. Survival of cancer patients, diagnosed in 1997–2016 in Slovenia, which is also available in pdf format at www.onko-i.si/rrs. Main conclusions are on the next page.

1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%).
2. Age and stage at diagnosis are still key when it comes to survival of cancer patients. Five-year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. The five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; the survival of patients with distant disease has not improved.
3. In both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), melanoma of skin (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). The improvement is due to earlier diagnosis and advances in systemic treatment.
4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased by 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased by over 20 percentage points. The improvement in prostate cancer survival is probably not real since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease.
5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers, as well as brain tumours.
6. In the CONCORD-3 study five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases, survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements.
7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemia, central nervous system tumours and lymphomas, and have a better five-year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five-year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%).

Comparisons with Europe

- According to the estimates of the European Cancer Information System (<https://ecis.jrc.ec.europa.eu/>), in 2020 Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (616/100,000). Ireland, Denmark, the Netherlands, Belgium, Cyprus, Hungary and France had a higher incidence.
- We are in seventh place in terms of mortality, led by Slovakia, Poland, Cyprus, Hungary, Croatia and Denmark.

Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2008–2017 in 2020.
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2008–2017 and 2020.

Šifra MKB	Primarna lokacija	Spol	Povprečne letne opazovane vrednosti 2008–2012		Povprečne letne opazovane vrednosti 2013–2017		Ocena za 2020			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število s 95 % napovednim intervalom		Incidenčna stopnja na 100.000 s 95 % napovednim intervalom	
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number with 95% prediction interval		Incidence rate per 100,000 with 95% prediction interval	
C00–C96	Vse lokacije All sites	M+ž M ž	13157 7162 5995	643,5 708 580,2	14632 7926 6706	709,3 775 644,7	8767 7484 16251	8518–9017 7249–7719 15909–16594	834 716 775	810–858 694–739 759–792
C00–C14	Usta in žrelo Mouth and pharynx	M ž	276 71	27,3 6,9	273 81	26,7 7,8	265 82	223–308 63–101	25 8	21–29 6–10
C15	Požiralnik Oesophagus	M ž	68 17	6,7 1,6	70 17	6,9 1,6	69 18	48–91 7–30	7 2	5–9 1–3
C16	Želodec Stomach	M ž	294 185	29,1 17,9	284 172	27,7 16,6	267 160	225–309 127–192	25 15	21–29 12–18
C18	Debelo črevo Colon	M ž	531 400	52,4 38,7	470 363	46 34,9	462 356	401–524 306–407	44 34	38–50 29–39
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M ž	415 247	41 23,9	355 204	34,7 19,6	315 171	270–361 138–203	30 16	26–34 13–19
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M ž	124 45	12,3 4,4	160 61	15,7 5,9	208 77	168–248 55–100	20 7	16–24 5–10
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M ž	69 102	6,9 9,9	86 107	8,4 10,3	103 108	75–132 81–135	10 10	7–13 8–13
C25	Trebušna slinavka Pancreas	M ž	169 181	16,7 17,5	199 191	19,4 18,4	224 202	183–264 164–239	21 19	17–25 16–23
C32	Grlo Larynx	M ž	92 11	9,1 1,1	87 12	8,5 1,1	84 11	60–108 0–21	8 1	6–10 0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M ž	868 370	85,9 35,8	927 495	90,6 47,6	946 660	865–1027 579–741	90 63	82–98 55–71
C43	Malignni melanom kože Malignant melanoma of skin	M ž	239 249	23,7 24,1	294 260	28,8 25	355 276	306–404 232–320	34 26	29–38 22–31
C44	Druge maligne neoplazme kože Skin, other malignomas	M ž	1086 1120	107,3 108,4	1426 1411	139,5 135,6	1794 1738	1683–1905 1621–1855	171 166	160–181 155–178
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M ž	28 38	2,8 3,7	31 43	3 4,2	31 49	16–46 30–68	3 5	2–4 3–6
C50	Dojka Breast	M ž	12 1218	1,2 117,9	12 1345	1,2 129,3	16 1474	4–28 1374–1575	1 141	0–3 131–151
C53	Maternični vrat Cervix uteri	M ž	– 132	– 12,8	– 113	– 10,9	– 97	– 74–120	– 9	– 7–12
C54	Maternično telo Corpus uteri	M ž	– 305	– 29,5	– 347	– 33,3	– 395	– 343–447	– 38	– 33–43
C56	Jajčnik Ovary	M ž	– 165	– 16	– 157	– 15,1	– 137	– 107–167	– 13	– 10–16
C61	Prostata Prostate	M ž	1469 –	145,2 –	1613 –	157,7 –	1775 –	1662–1888 –	169 –	158–180 –
C62	Modo Testis	M ž	104 –	10,2 –	117 –	11,4 –	137 –	105–169 –	13 –	10–16 –
C64–C65	Ledvica z ledvičnim mehonom Kidney with renal pelvis	M ž	236 118	23,3 11,5	259 138	25,3 13,2	280 143	236–325 111–175	27 14	22–31 11–17
C67	Sečni mehur Bladder	M ž	219 80	21,7 7,7	255 97	25 9,3	283 114	238–329 85–143	27 11	23–31 8–14
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M ž	78 64	7,7 6,2	104 74	10,2 7,1	122 82	94–151 59–106	12 8	9–14 6–10
C73	Ščitnica Thyroid gland	M ž	39 118	3,9 11,4	44 149	4,3 14,3	51 170	32–71 137–203	5 16	3–7 13–19
C81	Hodgkinov limfom Hodgkin's lymphoma	M ž	23 25	2,3 2,4	28 25	2,7 2,4	32 25	17–48 12–38	3 2	2–5 1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M ž	162 161	16 15,6	215 202	21 19,5	273 249	224–323 205–292	26 24	21–31 20–28
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M ž	69 63	6,8 6,1	73 61	7,2 5,9	82 58	58–106 38–78	8 6	5–10 4–7
C91–C95	Levkemije Leukaemias	M ž	160 124	15,9 12	182 137	17,8 13,2	201 148	172–230 116–180	19 14	16–22 11–17

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2017.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2017.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR* – World standard	SSS* – evropski standard ASR* – European standard	SSS* – slovenski standard ASR* – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	14987	725,4	340,9	484,9	575,6
		M	7974	777,2	387,6	563,9	681,9
		Ž	7013	674,2	307,8	430,3	502,2
C00–C14	Usta in žrelo Mouth and pharynx	M	265	25,8	13,9	19,4	22,0
		Ž	85	8,2	4,0	5,4	6,1
C15	Požiralnik Oesophagus	M	66	6,4	3,3	4,7	5,4
		Ž	22	2,1	0,7	1,1	1,5
C16	Želodec Stomach	M	251	24,5	10,9	17,0	21,1
		Ž	174	16,7	5,9	8,9	10,9
C18	Debelo črevo Colon	M	453	44,2	20,4	31,1	38,7
		Ž	330	31,7	12,6	18,5	22,4
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	337	32,8	16,0	23,7	28,3
		Ž	201	19,3	7,8	11,3	13,6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	189	18,4	8,9	13,1	16,0
		Ž	73	7,0	2,7	4,1	4,9
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	85	8,3	3,7	5,7	7,4
		Ž	110	10,6	3,4	5,4	6,7
C25	Trebušna slinavka Pancreas	M	203	19,8	9,2	14,1	17,5
		Ž	207	19,9	6,9	10,5	12,8
C32	Grlo Larynx	M	87	8,5	4,3	6,1	7,2
		Ž	7	0,7	0,4	0,5	0,6
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	887	86,5	41,8	61,8	74,2
		Ž	570	54,8	24,4	35,0	40,7
C43	Maligni melanom kože Malignant melanoma of skin	M	300	29,2	15,5	21,9	26,1
		Ž	278	26,7	15,3	20,1	22,7
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1547	150,8	69,6	106,5	132,3
		Ž	1609	154,7	61,5	89,9	108,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	28	2,7	1,4	2,0	2,5
		Ž	43	4,1	2,3	2,9	3,3
C50	Dojka Breast	M	10	1,0	0,5	0,7	0,9
		Ž	1399	134,5	71,4	96,6	109,2
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	86	8,3	4,9	6,4	7,1
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	351	33,7	15,9	22,7	26,0
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	157	15,1	7,3	10,2	11,8
C61	Prostata Prostate	M	1595	155,5	74,9	110,6	135,5
		Ž	–	–	–	–	–
C62	Modo Testis	M	125	12,2	12,1	12,5	13,3
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	282	27,5	14,3	20,3	23,8
		Ž	121	11,6	4,9	7,0	8,4
C67	Sečni mehur Bladder	M	255	24,9	10,9	17,2	21,8
		Ž	102	9,8	3,5	5,3	6,6
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M	116	11,3	7,2	9,2	10,3
		Ž	85	8,2	5,3	6,1	6,4
C73	Ščitnica Thyroid gland	M	47	4,6	2,9	3,7	4,2
		Ž	164	15,8	11,0	13,5	14,9
C81	Hodgkinov limfom Hodgkin's lymphoma	M	33	3,2	2,9	3,1	3,4
		Ž	24	2,3	2,7	2,6	2,8
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	191	18,6	9,6	13,7	16,7
		Ž	199	19,1	8,6	12,1	14,4
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	83	8,1	3,9	5,8	7,0
		Ž	58	5,6	2,4	3,3	3,8
C91–C95	Levkemije Leukaemias	M	193	18,8	11,8	14,9	17,1
		Ž	136	13,1	5,8	7,8	9,1

* SSS – starostno standardizirana incidenčna stopnja na 100.000
ASR – age standardized incidence rate per 100,000

Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2017.
Table 3: Cancer incidence by age and by sex with crude rate (CR) per 100,000 population and cumulative rate (CR), Slovenia 2017.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages		Starost / Age																		GS	KS 0-74
			0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+				
C00	Vse lokacije All sites	M+Ž	14987	25	8	11	28	44	64	130	228	370	573	872	1335	2007	2283	1973	2044	1653	1339	725,4	39,9	
C00		M	7974	18	3	8	14	29	37	68	77	131	206	402	689	1168	1421	1181	1147	848	527	777,2	46,1	
C00		Ž	7013	7	5	3	14	15	27	62	151	239	367	470	646	839	862	792	897	805	812	674,2	34,6	
C00	Ustnica Lip	M	20	0	0	0	0	0	0	0	0	0	0	1	0	2	4	3	5	1	4	1,9	0,1	
C00		Ž	10	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	3	2	3	1,0	0,0	
C01	Baza jezika Base of tongue	M	32	0	0	0	0	0	0	0	1	0	1	2	9	10	3	3	1	1	1	3,1	0,2	
C01		Ž	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0,4	0,0	
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	18	0	0	0	0	0	0	0	1	2	0	2	5	4	2	0	0	2	1,8	0,1		
C02		Ž	13	0	0	0	0	0	1	1	0	0	0	1	2	1	1	3	1	2	0	1,2	0,1	
C03	Dlesen Gum	M	6	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	1	0,6	0,0		
C03		Ž	7	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	1	2	0,7	0,0	
C04	Ustno dno Floor of mouth	M	19	0	0	0	0	0	0	0	1	3	3	2	5	4	1	0	0	0	0	1,9	0,1	
C04		Ž	4	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0	0	0	0,4	0,0	
C05	Nebo Palate	M	14	0	0	0	0	0	0	0	1	0	2	5	4	2	0	0	0	0	0	1,4	0,1	
C05		Ž	9	0	0	0	0	0	0	0	0	1	0	1	3	1	2	0	1	0	0,9	0,1		
C06	Usta, drugi deli Mouth, other & unspecified parts	M	17	0	0	0	0	0	0	0	1	0	3	5	3	1	1	2	0	1	1,7	0,1		
C06		Ž	4	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0	0	0,4	0,0		
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	1	1	0,6	0,0		
C07		Ž	8	0	0	0	0	0	1	1	1	0	0	0	0	2	0	0	3	0	0,8	0,0		
C08	Druga in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0,2	0,0		
C08		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0		
C09	Tonzila Tonsil	M	42	0	0	0	0	0	0	1	2	4	3	8	9	9	5	0	1	0	4,1	0,3		
C09		Ž	7	0	0	0	0	0	0	0	1	0	1	0	2	1	0	0	2	0	0,7	0,0		
C10	Orofaringks Oropharynx	M	22	0	0	0	0	0	0	0	1	2	2	3	4	6	3	0	1	0	2,1	0,2		
C10		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0,2	0,0		
C11	Nazofaringks Nasopharynx	M	6	0	0	0	0	0	1	0	0	0	0	2	1	1	1	0	0	0	0,6	0,0		
C11		Ž	3	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0,3	0,0		
C12	Piriformni sinus Pyriiform sinus	M	34	0	0	0	0	0	0	0	0	1	5	3	8	5	4	7	1	0	3,3	0,2		
C12		Ž	8	0	0	0	0	0	0	0	0	1	3	1	0	1	0	2	0	0	0,8	0,0		
C13	Hipofaringks Hypopharynx	M	26	0	0	0	0	0	0	0	1	1	5	7	6	1	2	1	2	2	2,5	0,2		
C13		Ž	5	0	0	0	0	0	0	0	0	0	1	3	0	1	0	0	0	0	0,5	0,0		
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0,1	0,0		
C14		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C15	Požiralnik Oesophagus	M	66	0	0	0	0	0	0	0	1	2	4	10	13	17	8	4	4	3	6,4	0,4		
C15		Ž	22	0	0	0	0	0	0	0	0	1	0	1	5	4	6	2	3	2,1	0,1			
C16	Želodec Stomach	M	251	0	0	0	0	0	1	0	2	2	10	20	38	33	38	44	36	27	24,5	1,2		
C16		Ž	174	0	0	0	1	0	1	1	3	5	2	11	13	23	21	28	28	37	16,7	0,7		
C17	Tanko črevo Small intestine	M	28	0	0	0	0	0	1	0	0	4	2	2	6	4	3	4	2	0	2,7	0,2		
C17		Ž	20	0	0	0	0	0	0	0	0	0	0	1	3	5	1	6	1	3	1,9	0,1		
C18	Debelo črevo Colon	M	453	0	0	0	0	1	0	3	7	9	27	24	57	73	75	65	72	40	44,2	2,4		
C18		Ž	330	0	0	0	1	0	2	2	5	15	24	19	26	37	51	50	58	40	31,7	1,5		
C19	Rektosigmoidna zveza Rectosigmoid junction	M	62	0	0	0	0	0	0	0	2	1	3	6	5	11	12	9	11	2	6,0	0,4		
C19		Ž	56	0	0	0	0	0	1	0	2	3	4	1	4	4	6	10	11	10	5,4	0,2		
C20	Rektum Rectum	M	275	0	0	0	0	1	0	2	8	6	18	37	47	39	31	36	33	17	26,8	1,5		
C20		Ž	145	0	0	0	0	0	1	5	3	3	9	7	25	16	19	21	17	19	13,9	0,7		
C21	Anus in analni kanal Anus and anal canal	M	4	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	1	0	0,4	0,0		
C21		Ž	10	0	0	0	0	0	0	0	0	1	1	2	1	0	2	2	0	1	1,0	0,1		
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	189	0	0	0	0	0	0	0	0	6	8	15	29	49	30	23	20	9	18,4	1,2		
C22		Ž	73	0	0	0	0	0	0	1	0	0	5	7	9	13	8	13	9	8	7,0	0,3		
C23	Žolčnik Gallbladder	M	19	0	0	0	0	0	0	0	1	0	0	3	5	2	6	2	6	2	1,9	0,1		
C23		Ž	47	0	0	0	0	0	0	0	0	0	2	4	6	5	4	9	7	10	4,5	0,2		
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspec- ified parts	M	66	0	0	0	0	0	0	1	0	0	0	3	11	13	16	11	9	2	6,4	0,4		
C24		Ž	63	0	0	0	0	0	0	0	0	0	4	3	6	3	11	10	13	13	6,1	0,2		
C25	Trebušna slinavka Pancreas	M	203	0	0	0	0	1	1	1	2	2	11	18	21	36	34	40	25	11	19,8	1,1		
C25		Ž	207	0	0	0	0	0	0	1	4	4	5	14	21	26	20	35	40	37	19,9	0,7		

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages		Starost / Age																	GS	KS 0-74	
			0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+				
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0,2	0,0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,1	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	2	1	1	0,7	0,0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0,2	0,0
C31	Obnosni sinusi Accessory sinuses	M	5	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	0	0,5	0,0
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	1	0,5	0,0
C32	Grlo Larynx	M	87	0	0	0	0	0	0	0	0	0	2	4	9	22	24	9	12	4	1	8,5	0,6	
		Ž	7	0	0	0	0	0	0	0	0	0	1	0	2	1	1	1	1	0	0	0,7	0,0	
C33	Sapnik Trachea	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	0,5	0,0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0,1	0,0
C34	Sapnica in pljuča Bronchus and lung	M	882	0	0	0	0	0	0	0	1	6	6	49	103	154	190	137	113	73	50	86,0	5,5	
		Ž	569	0	0	0	1	0	0	0	3	2	12	25	78	104	110	77	80	44	33	54,7	3,2	
C37	Timus Thymus	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0,4	0,0	
		Ž	6	0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	0	0	0,6	0,0	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	2	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0,2	0,0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0,3	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	5	0	0	0	2	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0,5	0,0	
		Ž	4	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0,4	0,0	
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	5	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0	1	0,5	0,0	
		Ž	7	0	0	1	1	0	0	0	0	0	0	0	2	1	1	0	1	0	0	0,7	0,1	
C43	Malignni melanom kože Malignant melanoma of skin	M	300	0	0	0	0	2	1	4	10	15	16	21	24	45	45	38	39	22	18	29,2	1,8	
		Ž	278	0	1	0	2	1	4	9	12	21	28	27	31	20	26	31	25	17	23	26,7	1,6	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1547	0	0	0	0	3	5	8	15	30	49	67	107	158	229	212	268	238	158	150,8	7,5	
		Ž	1609	0	0	0	0	3	7	26	56	63	93	108	155	160	201	241	237	259	154,7	6,8		
C45	Mezoteliom Mesothelioma	M	35	0	0	0	0	0	0	0	0	0	0	2	1	7	8	3	5	7	2	3,4	0,2	
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2	1	0	0,8	0,0	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0,2	0,0	
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0,1	0,0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	6	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	3	0	0,6	0,0	
		Ž	18	0	0	0	0	0	0	0	0	0	0	1	2	3	5	2	3	1	1	1,7	0,1	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	22	0	0	0	0	0	0	0	1	1	1	3	1	2	4	4	3	1	1	2,1	0,1	
		Ž	25	1	0	0	0	1	0	1	3	1	1	3	2	0	2	2	2	3	3	2,4	0,1	
C50	Dojka Breast	M	10	0	0	0	0	0	0	0	1	0	1	0	0	2	3	1	2	0	0	1,0	0,1	
		Ž	1399	0	0	0	0	1	4	10	50	86	137	135	164	198	177	115	123	111	88	134,5	7,9	
C51	Žensko zunanje spolovilo Vulva	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	58	0	0	0	0	0	0	0	0	0	2	5	3	6	12	9	10	11	5,6	0,2		
C52	Nožnica Vagina	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	12	0	0	0	0	0	1	0	0	1	0	0	2	2	1	0	1	2	2	1,2	0,1	
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	86	0	0	0	0	0	6	13	3	8	8	10	8	10	5	1	4	10	8,3	0,5		
C54	Maternično telo Corpus uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	351	0	0	0	0	0	1	3	7	14	31	53	57	48	45	50	19	23	33,7	2,0		
C55	Maternica, neopredeljeno Uterus, unspecified	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	20	0	0	0	0	0	0	0	0	1	2	1	3	1	2	4	1	3	1,9	0,1		
C56	Jajčnik Ovary	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	157	0	0	0	1	0	1	3	2	11	14	17	20	25	21	18	13	11	15,1	0,9		
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	25	0	0	0	0	0	0	0	0	0	1	5	6	2	6	1	2	2	2,4	0,2		

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74			
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+		
C58	Posteljica Placenta	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,1	0,0
C60	Penis Penis	M	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,2	0,1
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostata Prostate	M	1595	0	0	0	0	0	0	0	0	0	0	9	56	144	283	393	315	229	113	53	155,5	10,6	
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Modo Testis	M	125	2	0	0	2	16	17	28	20	14	15	5	2	4	0	0	0	0	0	0	0	12,2	0,9
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0,3	0,0	
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Ledvica razen meha Kidney, except renal pelvis	M	261	1	0	0	0	0	1	0	2	7	15	18	33	48	46	30	28	18	14	25,4	1,6		
		Ž	104	0	0	0	0	0	0	1	1	1	6	7	5	15	16	13	14	18	7	10,0	0,5		
C65	Ledvični meh Renal pelvis	M	21	0	0	0	0	0	0	0	0	0	0	2	1	2	4	4	3	4	1	2,0	0,1		
		Ž	17	0	0	0	0	0	1	0	0	0	1	0	1	3	0	3	0	5	3	1,6	0,1		
C66	Sečevod Ureter	M	9	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	3	0	0,9	0,0		
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1	0,6	0,0		
C67	Sečni mehur Bladder	M	255	0	0	0	0	0	0	0	0	2	5	14	15	28	29	39	52	32	39	24,9	1,2		
		Ž	102	0	0	0	0	0	0	1	0	0	3	3	1	15	15	14	18	13	19	9,8	0,4		
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0,1	0,0	
C69	Oko in očesni adneksi Eye and adnexa	M	9	1	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	3	0,9	0,0		
		Ž	11	0	0	0	0	0	0	0	1	0	0	0	1	2	2	2	1	0	2	1,1	0,1		
C70	Meninge Meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0,1	0,0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0,2	0,0		
C71	Možgani Brain	M	114	3	0	0	0	1	2	2	6	5	11	15	13	11	13	9	13	7	3	11,1	0,7		
		Ž	81	4	2	0	1	0	3	0	1	4	4	6	8	8	10	7	4	11	8	7,8	0,5		
C72	Hrbtini mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,1	0,0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0,2	0,0	
C73	Ščitnica Thyroid gland	M	47	0	0	0	1	0	0	2	3	2	8	2	7	8	6	4	3	1	0	4,6	0,3		
		Ž	164	0	0	0	1	5	6	10	7	10	25	12	24	17	19	14	9	5	0	15,8	1,1		
C74	Nadledvična žleza Adrenal gland	M	8	2	0	0	1	0	0	1	0	0	2	0	0	0	0	0	1	0	1	0,8	0,0		
		Ž	5	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	1	0	0	0,5	0,0		
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	4	0	0	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0,4	0,0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0,1	0,0		
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	2	3	1,0	0,0		
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	24	0	0	0	0	0	0	0	0	1	0	2	3	8	1	2	4	0	3	2,3	0,1		
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	0	1	0	0,6	0,0		
C78	Metastaze dihal in prebavi Metastases of respiratory and digestive organs	M	23	0	0	0	0	0	0	0	0	0	0	0	1	4	2	5	2	2	7	2,2	0,1		
		Ž	42	0	0	0	0	0	0	0	0	1	0	0	2	0	2	1	4	8	24	4,0	0,0		
C79	Metastaze, drugje Metastases of other sites	M	11	0	0	0	0	0	0	0	0	1	0	0	1	0	6	1	0	2	0	1,1	0,1		
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1	1	0	0,6	0,0		
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	47	0	0	0	0	0	0	1	0	1	0	3	5	5	8	6	6	7	5	4,6	0,2		
		Ž	64	0	0	0	0	0	0	0	2	1	3	2	5	7	8	3	10	14	9	6,2	0,2		
C81	Hodgkinov limfom Hodgkin's lymphoma	M	33	0	0	1	3	2	4	3	3	3	1	2	2	0	3	2	2	2	0	3,2	0,2		
		Ž	24	0	0	1	2	5	3	3	3	2	1	0	0	0	0	1	1	1	1	2,3	0,2		
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	45	0	0	0	1	0	1	2	0	3	0	2	3	7	3	4	9	6	4	4,4	0,2		
		Ž	64	0	0	0	0	0	0	1	3	8	1	7	5	6	13	7	7	4	2	6,2	0,4		
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	122	0	0	0	1	1	0	3	2	2	7	3	6	17	12	16	23	23	6	11,9	0,6		
		Ž	113	0	0	0	1	0	1	2	1	1	2	5	6	12	18	9	27	12	16	10,9	0,5		

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74	
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	13	1	0	0	0	1	0	2	0	1	1	0	1	2	1	1	0	1	1	1,3	0,1
		Ž	13	0	0	0	1	0	0	0	0	0	0	0	1	0	2	5	2	1	1	1,2	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	11	0	0	0	0	0	0	0	1	0	0	0	0	2	2	2	4	0	1,1	0,0	
		Ž	9	0	0	0	0	0	0	0	0	0	0	2	1	0	2	2	0	2	0,9	0,0	
C88	Malignne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0,2	0,0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0,1	0,0	
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	83	0	0	0	1	0	1	0	0	1	7	7	13	16	9	14	7	7	8,1	0,5	
		Ž	58	0	0	0	0	0	0	1	2	1	5	4	12	8	2	6	10	7	5,6	0,3	
C91.0	Limfoblastna levkemija Lymphocytic leukaemia, acute	M	19	6	2	3	1	0	1	1	0	1	2	0	1	0	0	1	0	0	1,9	0,2	
		Ž	7	2	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0,7	0,0	
C91.1- C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	75	0	0	0	0	1	0	0	1	4	5	6	10	9	11	14	8	6	7,3	0,4	
		Ž	47	0	0	0	0	0	0	0	1	1	3	0	5	4	7	8	5	13	4,5	0,2	
C92	Mieločna levkemija Myeloid leukaemia	M	78	1	0	1	0	1	1	3	1	2	1	5	10	13	16	9	7	6	7,6	0,5	
		Ž	60	0	0	1	0	0	0	4	3	4	3	6	4	7	7	3	8	10	5,8	0,3	
C93	Monocitna levkemija Monocytic leukaemia	M	6	0	0	0	0	0	1	0	0	1	0	1	0	1	0	1	0	1	0,6	0,0	
		Ž	5	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	3	0	0,5	0,0	
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	12	0	0	1	0	0	0	0	0	0	0	2	1	1	3	2	1	1	1,2	0,1	
		Ž	11	0	0	0	0	0	0	0	0	1	0	0	1	2	0	2	2	3	1,1	0,0	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0,3	0,0	
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	1	0,6	0,0	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	94	1	1	0	0	1	2	0	2	1	4	0	14	9	12	24	15	8	9,2	0,4	
		Ž	87	0	0	0	1	0	0	1	2	3	3	5	3	6	8	11	17	10	8,4	0,3	

Zgoraj neupoštevani:
Not included above:

D03	Melanom, in situ Melanoma, in situ	M	125	0	0	0	0	1	1	2	5	8	6	14	7	15	18	12	13	14	9	12,2	0,7
		Ž	149	0	0	0	0	1	4	5	12	10	12	13	9	12	20	15	20	12	4	14,3	0,9
D05	Dojka, in situ Breast, in situ	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0,1	0,0
		Ž	170	0	0	0	0	0	0	1	0	8	21	29	28	30	36	10	3	2	2	16,3	1,2
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	1123	0	0	0	0	92	193	227	200	125	85	73	45	41	22	9	10	1	0	108,0	8,4
D09.0	Sečni mehur, in situ Bladder, in situ	M	193	0	0	0	0	0	0	0	0	2	4	8	16	21	42	30	33	22	15	18,8	1,1
		Ž	63	0	0	0	0	0	1	0	1	0	1	2	4	8	10	12	8	9	7	6,1	0,3
D32.0, D42.0	Meninge, benigna neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	39	0	0	0	0	1	0	0	2	1	2	3	2	4	5	6	6	4	3	3,8	0,2
		Ž	114	0	0	0	0	0	2	4	2	3	9	9	10	18	14	8	15	11	9	11,0	0,6
D33.0- D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	3	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0,3	0,0
		Ž	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,2	0,0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	71	0	0	1	0	0	4	2	3	7	7	6	8	13	8	3	4	3	2	6,8	0,5
D43.0- D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	13	0	1	0	1	0	1	2	0	0	0	0	0	1	2	2	1	2	1,3	0,1	
		Ž	9	0	1	1	1	0	1	0	1	0	0	1	0	0	0	1	2	0	0	0,9	0,1

Tabela 4a: Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2017.
 Table 4a: Incidence of microscopically (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2017.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																			
		Primary site (ICD code)																			
		C00-C80	C00	C01	C02	C03	C04	C05	C06	C07	C08	C09	C10	C11	C12	C13	C14	C15	C16	C17	C18
Vse vrste / All types	13175	30	36	31	13	23	23	21	14	3	49	24	9	42	31	0	83	413	48	765	
Small cell carcinoma	220	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	
Non-small cell carcinoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1509	30	36	29	12	23	19	20	1	1	48	22	8	42	30	0	60	4	0	0	
Basal cell carcinoma	2620	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	372	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Adenocarcinoma	6881	0	0	1	0	0	3	0	10	1	0	1	0	0	0	0	20	368	35	756	
Other specified carcinomas	122	0	0	0	1	0	1	1	2	0	1	0	0	0	0	0	0	3	0	0	
Carcinoma, unspecified	169	0	0	0	0	0	0	0	0	1	0	1	1	0	1	0	2	9	0	8	
Malignant thymoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	613	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	
Rhabdomyosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Angiosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified sarcomas	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Sarcoma, unspecified	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant complex mixed and stromal tumors	83	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	27	13	0	
Malignant fibroepithelial tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dysgerminoma and seminoma	76	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other malignant germ cell tumors	52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gliomas	168	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	

Nadaljevanje —>
 Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00-C80	C19	C20	C21	C22	C23	C24	C25	C26	C30	C31	C32	C33	C34	C37	C38	C39	C40	C41
Vse vrste / All types	13175	112	412	13	150	48	87	270	2	9	10	94	6	1353	10	4	0	9	11	578
Small cell carcinoma	220	0	0	0	1	0	1	1	0	0	0	0	2	200	0	0	0	0	0	0
Non-small cell carcinoma	89	0	0	0	0	0	0	0	0	0	0	0	0	88	0	0	0	0	0	0
Squamous cell carcinoma	1509	0	1	10	0	0	0	0	0	4	6	94	3	340	1	0	0	0	0	0
Basal cell carcinoma	2620	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	372	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6881	110	404	2	147	39	81	240	0	2	1	0	1	657	0	0	0	0	0	0
Other specified carcinomas	122	1	0	0	1	5	0	7	0	0	0	0	0	38	0	0	0	0	0	0
Carcinoma, unspecified	169	1	6	0	1	3	5	21	0	0	0	0	0	25	0	0	0	0	0	0
Malignant thymoma	9	0	0	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	613	0	1	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	578
Fibrosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Liposarcoma	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
Angiosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0
Chondrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	6	0
Ewing sarcoma/PNET	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0
Other specified sarcomas	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	0	0	1	0
Malignant complex mixed and stromal tumors	83	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	76	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	52	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	168	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	7	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Malignant tumor, unspecified	12	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00–C80	C44	C45	C46	C47	C48	C49	C50	C51	C52	C53	C54	C55	C56	C57	C58	C60	C61	C62
Vse vrste / All types	13175	3147	43	0	3	24	47	1398	58	12	85	349	14	147	24	1	12	1545	125	
Small cell carcinoma	220	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	
Non-small cell carcinoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1509	492	0	0	0	0	0	0	49	9	67	0	0	1	0	0	12	0	0	
Basal cell carcinoma	2620	2615	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	372	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	
Adenocarcinoma	6881	26	0	0	0	13	0	1355	2	1	16	288	0	128	23	0	0	1534	0	
Other specified carcinomas	122	0	0	0	0	0	0	9	0	0	0	34	0	3	0	0	0	1	0	
Carcinoma, unspecified	169	2	0	0	0	0	0	33	0	0	0	3	0	3	1	0	0	3	0	
Malignant thymoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	613	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	
Fibrosarcoma	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	11	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	16	0	0	0	0	2	13	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	19	1	0	0	0	2	9	0	0	0	0	5	0	0	0	0	0	0	0	
Rhabdomyosarcoma	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	4	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Angiosarcoma	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	6	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	11	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	5	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified sarcomas	4	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	
Sarcoma, unspecified	21	0	0	0	0	3	12	0	0	0	0	1	0	0	0	0	0	0	0	
Malignant complex mixed and stromal tumors	83	0	0	0	0	1	1	0	0	0	2	22	8	3	0	0	0	0	0	
Malignant fibroepithelial tumors	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	43	0	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	
Dysgerminoma and seminoma	76	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	75	
Other malignant germ cell tumors	52	0	0	0	0	2	0	0	0	0	0	1	0	2	0	0	0	0	44	
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	6	
Malignant gliomas	168	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	4	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	12	0	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	

Nadaljevanje —>
Continued —>

Tabela 4a: Nadaljevanje.
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																	
		Primary site (ICD code)																	
		C00–C80	C63	C64	C65	C66	C67	C68	C69	C70	C71	C72	C73	C74	C75	C76	C77	C78	C79
Vse vrste / All types	13175	3	326	36	13	351	1	20	3	168	3	211	13	4	7	28	27	14	77
Small cell carcinoma	220	0	0	0	0	6	0	0	0	0	0	0	0	0	1	2	0	2	0
Non-small cell carcinoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Squamous cell carcinoma	1509	0	0	1	0	7	0	2	0	0	0	0	0	0	0	17	0	1	7
Basal cell carcinoma	2620	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	372	0	0	31	12	322	1	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6881	0	321	0	0	2	0	0	0	0	0	203	3	2	2	5	21	8	49
Other specified carcinomas	122	0	0	0	0	1	0	0	0	0	0	8	1	0	0	3	0	1	0
Carcinoma, unspecified	169	0	4	3	1	13	0	0	0	0	0	0	0	0	2	0	5	0	11
Malignant thymoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	7	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0
Malignant melanoma	613	0	0	0	0	0	0	17	1	0	0	0	0	0	0	1	0	2	6
Fibrosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	16	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	5	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	4	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	83	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Malignant fibroepithelial tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	76	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Other malignant germ cell tumors	52	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	168	0	0	0	0	0	0	0	0	166	2	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	7	0	0	0	0	0	0	1	0	2	0	0	2	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	4	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Other specified malignant tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	12	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	3

Tabela 4b:

Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2017.

Table 4b:

Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2017.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
Vse vrste All types	Moški in ženske / Males and females	743
	Moški / Males	405
	Ženske / Females	338
9727, 9728, 9835, 9836, 9811-9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	21
9728, 9835, 9811, 9813, 9815	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	21
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	7
9729, 9837	Limfoblastni limfom T / levkemija T T Lymphoblastic lymphoma / leukaemia	7
9591-9597, 9670-9699, 9712, 9731-9738, 9760-9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	623
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	135
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	12
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	16
9940	Dlakastocelična levkemija Hairy cell leukaemia	3
9671	Limfoplazmactni limfom Lymphoplasmacytic lymphoma	7
9761	Waldenströmova makroglobulinemija Waldenström macroglobulinemia	3
9732, 9733	Multipli mielom Plasma cell myeloma	133
9731, 9734	Solitarni kostni in zunajkostni plazmactom Solitary plasmacytoma of bone and extraosseous	8
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	23
9699, ekstranodalni	B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal	32
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	4
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	36
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	14
9673	Limfom plaščnih celic Mantle cell lymphoma	30
9735	Plazmablastni limfom Plasmablastic lymphoma	1
9680	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL ČŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	155
9687	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	3

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	7
9596	Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasičnega Hodgkinovega limfoma B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL	1
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	28
9827, 9831, 9834, 9948	Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	2
9831	Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	2
9700, 9701, 9708, 9709, 9716-9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	10
9717	Limfom T z enteropatijo Enteropathy-associated T-cell lymphoma	2
9700	Fungoidna mikoza Mycosis fungoides	4
9701	Sézaryjev sindrom Sézary syndrome	1
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	2
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	1
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	16
9702	Periferni limfom T (BDO- in ALK-negativen ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	10
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	2
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	4
9650-9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	57
9659	HL z nodularno limfocitno predomnanco Nodular lymphocyte predominant HL	2
9650	Klasični HL Classical HL	4
9663, 9664, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	31
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	5
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	14
9653	Klasični HL, tip limfocitne delecije Lymphocyte-depleted classical HL	1
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia	3
9590	Maligni limfom, BDO Malignant lymphoma, NOS	3
9750-9759	Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	4
9751	Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS	3
9757	Sarkom interdigitatnih dendritičnih celic Interdigitating dendritic cell sarcoma	1

Tabela 4c: Incidenca ne-Hodgkinovih limfomov po lokaciji, Slovenija 2017.
 Table 4c: Incidence of non-Hodgkin's malignant lymphomas by cancer site, Slovenia 2017.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Vse starosti All ages
	Vsi NHL All NHL	390
142	Slinavke Salivary glands	5
145	Usta, drugo Mouth, other parts	2
146	Orofarinks Oropharynx	11
147	Epifarinks Epipharynx	1
151	Želodec Stomach	22
152	Tanko črevo Small intestine	4
153	Debelo črevo Colon	6
157	Trebušna slinavka Pancreas	1
160	Nos, obnosne votline, drugo Nos, obnosne votline, drugo	1
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	5
163	Plevra, mediastinum, drugo Pleura, mediastinum, etc.	3
170	Kosti Bone	3
171	Mehka tkiva Soft tissues	1
173	Koža, drugi malignomi Skin, other malignancies	14
174	Dojka Breast	2
182	Maternica, telo, drugo Uterus, corpus, etc.	1
183	Jajčnik, jajcevod, drugo Ovary, Fallopian tube, other	1
186	Modo Testis	1
188	Mehur Bladder	1
190	Oko Eye	6
191	Možgani Brain	13
193	Ščitnica Thyroid	2
202	Bezgavke Lymph nodes	284

Tabela 5: Incidenca raka po stadiju, Slovenija 2017.
Table 5: Cancer incidence by stage, Slovenia 2017.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznano Unknown **	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C00-C80	Moški in ženske / Males and females	12744	7704	60,5	3384	26,6	2537	19,9	261,0	2,0
	Vse lokacije / All sites	6765	3995	59,1	1868	27,6	1347	19,9	168,0	2,5
	Moški / Males	5979	3709	62,0	1516	25,4	1190	19,9	93,0	1,6
	Ženske / Females									
C00	Ustnica / Lip	30	28	93,3	2	6,7	0	0,0	0	0,0
C01	Baza jezika / Base of tongue	36	5	13,9	29	80,6	2	5,6	0	0,0
C02	Jezik, drugi deli / Tongue, other & unspecified parts	31	15	48,4	16	51,6	0	0,0	0	0,0
C03	Dlesen / Gum	13	3	-	10	-	0	-	0	-
C04	Ustno dno / Floor of mouth	23	7	30,4	15	65,2	1	4,3	0	0,0
C05	Nebo / Palate	23	6	26,1	16	69,6	1	4,3	0	0,0
C06	Usta, drugi deli / Mouth, other & unspecified parts	21	3	14,3	18	85,7	0	0,0	0	0,0
C07	Parotidna žleza / Parotid gland	14	6	-	7	-	1	-	0	-
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	3	0	-	2	-	1	-	0	-
C09	Tonzila / Tonsil	49	9	18,4	39	79,6	1	2,0	0	0,0
C10	Orofaring / Oropharynx	24	3	12,5	20	83,3	1	4,2	0	0,0
C11	Nazofaring / Nasopharynx	9	0	-	7	-	2	-	0	-
C12	Piriformni sinus / Pyriform sinus	42	5	11,9	34	81,0	3	7,1	0	0,0
C13	Hipofaring / Hypopharynx	31	2	6,5	27	87,1	2	6,5	0	0,0
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	1	0	-	1	-	0	-	0	-
C15	Požiralnik / Oesophagus	88	5	5,7	47	53,4	28	31,8	8	9,1
C16	Želodec / Stomach	425	75	17,6	151	35,5	174	40,9	25	5,9
C17	Tanko črevo / Small intestine	48	15	31,3	18	37,5	15	31,3	0	0,0
C18	Debelo črevo / Colon	783	169	21,6	398	50,8	195	24,9	21	2,7
C19	Rektosigmoidna zveza / Rectosigmoid junction	118	22	18,6	58	49,2	36	30,5	2	1,7
C20	Rektum / Rectum	420	73	17,4	234	55,7	103	24,5	10	2,4
C21	Anus in analni kanal / Anus and anal canal	14	5	-	7	-	2	-	0	-
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	262	81	30,9	71	27,1	96	36,6	14	5,3
C23	Žolčnik / Gallbladder	66	15	22,7	15	22,7	34	51,5	2	3,0
C24	Druge in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	129	17	13,2	53	41,1	53	41,1	6	4,7
C25	Trebušna slinavka / Pancreas	410	35	8,5	150	36,6	209	51,0	16	3,9
C26	Druge in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	3	0	-	0	-	2	-	1	-
C30	Nosna votlina in srednje uho / Nasal cavity and middle ear	9	2	-	7	-	0	-	0	-
C31	Obnosni sinusi / Accessory sinuses	10	0	-	10	-	0	-	0	-
C32	Grla / Larynx	94	51	54,3	43	45,7	0	0,0	0	0,0
C33	Sapnik / Trachea	6	0	-	1	-	4	-	1	-
C34	Sapnica in pljuča / Bronchus and lung	1451	245	16,9	450	31,0	740	51,0	16	1,1
C37	Timus / Thymus	10	7	-	3	-	0	-	0	-
C38	Srce, mediastinum, plevra / Heart, mediastinum, pleura	5	0	-	1	-	2	-	2	-
C39	Druge in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	-	0	-	0	-	0	-
C40	Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs	9	3	-	2	-	4	-	0	-
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	12	1	-	7	-	4	-	0	-
C43	Maligni melanom kože / Malignant melanoma of skin	578	437	75,6	132	22,8	8	1,4	1	0,2
C44	Druge maligne neoplazme kože / Skin, other malignomas	3156	3131	99,2	20	0,6	1	0,0	4	0,1
C45	Mezoteliom / Mesothelioma	43	10	23,3	25	58,1	5	11,6	3	7,0
C46	Kaposijev sarkom / Kaposi's sarcoma	0	0	-	0	-	0	-	0	-
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	3	1	-	1	-	1	-	0	-
C48	Peritonej in retroperitonej / Retroperitoneum and peritoneum	24	1	4,2	8	33,3	15	62,5	0	0,0
C49	Drugo vezivno in mehko tkivo / Other connective and soft tissue	47	22	46,8	19	40,4	4	8,5	2	4,3
C50	Dojka / Breast	1409	809	57,4	478	33,9	111	7,9	11	0,8

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznan Unknown**	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C51	Žensko zunanje spolovilo / Vulva	58	26	44,8	29	50,0	3	5,2	0	0,0
C52	Nožnica / Vagina	12	6	-	5	-	0	-	1	-
C53	Maternični vrat / Cervix uteri	86	39	45,3	38	44,2	8	9,3	1	1,2
C54	Maternično telo / Corpus uteri	351	244	69,5	70	19,9	27	7,7	10	2,8
C55	Maternica, neopredeljeno / Uterus, unspecified	20	9	45,0	5	25,0	4	20,0	2	10,0
C56	Jajčnik / Ovary	157	19	12,1	14	8,9	123	78,3	1	0,6
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	25	1	4,0	2	8,0	22	88,0	0	0,0
C58	Posteljica / Placenta	1	0	-	0	-	1	-	0	-
C60	Penis / Penis	12	9	-	2	-	1	-	0	-
C61	Prostata / Prostate	1595	1049	65,8	359	22,5	132	8,3	55	3,4
C62	Modo / Testis	125	96	76,8	18	14,4	11	8,8	0	0,0
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	3	2	-	0	-	1	-	0	-
C64	Ledvica razen meha / Kidney, except renal pelvis	365	218	59,7	54	14,8	86	23,6	7	1,9
C65	Ledvični meh / Renal pelvis	38	11	28,9	11	28,9	16	42,1	0	0,0
C66	Sečevod / Ureter	15	5	33,3	7	46,7	2	13,3	1	6,7
C67	Sečni mehur / Bladder	357	264	73,9	58	16,2	27	7,6	8	2,2
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	1	1	-	0	-	0	-	0	-
C69	Oko in očesni adneksi / Eye and adnexa	20	18	90,0	2	10,0	0	0,0	0	0,0
C70	Meninge / Meninges	3	2	-	0	-	1	-	0	-
C71	Možgani / Brain	195	195	100,0	0	0,0	0	0,0	0	0,0
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	3	2	-	1	-	0	-	0	-
C73	Ščitnica / Thyroid gland	211	154	73,0	49	23,2	8	3,8	0	0,0
C74	Nadledvična žleza / Adrenal gland	13	8	-	2	-	2	-	1	-
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	4	1	-	2	-	1	-	0	-
C76	Druga in slabo opredeljena mesta / Other and ill-defined sites	11	1	-	4	-	6	-	0	-
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	30	0	0,0	0	0,0	1	3,3	29	96,7
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	65	0	0,0	0	0,0	65	100,0	0	0,0
C79	Metastaze, drugje / Metastases of other sites	17	0	0,0	0	0,0	17	100,0	0	0,0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	111	0	0,0	0	0,0	111	100,0	0	0,0

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			I		II		III + IV		Neznan / Unknown	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C81	Hodgkinov limfom / Hodgkin's lymphoma	57	7	12,3	20	35,1	30	52,6	0	0,0
C82	Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin's lymphoma	109	30	27,5	9	8,3	65	59,6	5	4,6
C83	Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin's lymphoma	235	40	17,0	23	9,8	152	64,7	20	8,5
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	26	9	34,6	2	7,7	14	53,8	1	3,8
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	20	5	25,0	2	10,0	8	40,0	5	25,0

* Odstotki niso računani, če je število novih primerov manjše od 15
Percentages are not calculated when number of new cases is less than 15

** Vključeni tudi primeri, ki so registrirani samo iz zdravniških poročil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju
Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage

Tabela 6: Prevalenca po spolu, Slovenija, 31. 12. 2017.
Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2017.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1-4	5-9	10+	Vsi / All
C00-C96	Vse lokacije All sites	M+Ž	12286	35267	30248	41417	111696
		M	6404	18146	15081	15417	50941
		Ž	5882	17121	15167	26000	60755
C00-C14	Usta in žrelo Mouth and pharynx	M	229	550	445	491	1715
		Ž	76	226	166	277	745
C15	Požiralnik Oesophagus	M	38	40	16	24	118
		Ž	12	13	6	11	42
C16	Želodec Stomach	M	163	362	260	400	1185
		Ž	110	220	186	355	871
C18	Debelo črevo Colon	M	375	1130	1173	1010	3688
		Ž	276	870	909	1095	3150
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	284	904	910	889	2987
		Ž	168	491	555	787	2001
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	89	96	26	20	231
		Ž	35	33	8	12	88
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	44	64	34	33	175
		Ž	49	68	34	40	191
C25	Trebušna slinavka Pancreas	M	108	73	29	22	232
		Ž	99	79	30	29	237
C32	Grlo Larynx	M	83	217	226	342	868
		Ž	6	33	30	57	126
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	515	765	354	398	2032
		Ž	389	578	234	201	1402
C43	Malignni melanom kože Malignant melanoma of skin	M	291	996	798	925	3010
		Ž	271	906	961	1534	3672
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1519	4861	3785	4091	14256
		Ž	1584	4862	4103	5131	15680
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	24	73	64	203	364
		Ž	36	104	70	211	421
C50	Dojka Breast	M	10	38	34	33	115
		Ž	1348	4611	4299	7610	17868
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	78	343	419	2651	3491
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	325	1109	1025	2325	4784
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	127	313	273	880	1593
C61	Prostata Prostate	M	1510	5383	4757	2491	14141
		Ž	-	-	-	-	-
C62	Modo Testis	M	125	449	493	1463	2530
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	227	617	584	659	2087
		Ž	89	357	284	480	1210
C67	Sečni mehur Bladder	M	217	539	384	431	1571
		Ž	80	189	107	152	528
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	79	110	71	198	458
		Ž	55	75	58	158	346
C73	Ščitnica Thyroid gland	M	46	143	151	243	583
		Ž	161	539	527	1040	2267
C81	Hodgkinov limfom Hodgkin's lymphoma	M	29	89	90	360	568
		Ž	24	91	102	330	547
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	141	558	402	539	1640
		Ž	165	495	418	568	1646
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	67	149	84	53	353
		Ž	49	130	75	48	302
C91-C95	Levkemije Leukaemias	M	144	366	268	410	1188
		Ž	98	292	221	355	966

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat
For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2017. Vir: Nacionalni inštitut za javno zdravje
 Table 7: Cancer mortality by age and by sex, Slovenia 2017. Source: National Institute of Public Health

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age			
				0-19	20-49	50-74	75+
C00-C97	Vse lokacije All sites	M+Ž	6365	12	205	2982	3166
		M	3570	6	96	1815	1653
		Ž	2795	6	109	1167	1513
C00-C14	Usta in žrelo Mouth and pharynx	M	120	0	6	93	21
		Ž	24	0	2	13	9
C15	Požiralnik Oesophagus	M	73	0	8	51	14
		Ž	21	0	0	11	10
C16	Želodec Stomach	M	201	0	2	99	100
		Ž	129	1	4	43	81
C18	Debelo črevo Colon	M	252	0	8	104	140
		Ž	176	0	6	49	121
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	164	0	4	77	83
		Ž	111	0	3	39	69
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	198	0	3	131	64
		Ž	85	0	1	42	42
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	46	0	0	20	26
		Ž	71	0	0	24	47
C25	Trebušna slinavka Pancreas	M	190	0	4	103	83
		Ž	194	0	2	84	108
C32	Grlo Larynx	M	59	0	2	40	17
		Ž	5	0	0	4	1
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	787	0	10	528	249
		Ž	458	0	8	281	169
C43	Maligni melanom kože Malignant melanoma of skin	M	59	0	4	34	21
		Ž	52	0	5	17	30
C44	Druge maligne neoplazme kože Skin, other malignomas	M	20	0	0	6	14
		Ž	30	0	0	1	29
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	20	0	4	10	6
		Ž	33	0	4	12	17
C50	Dojka Breast	M	2	0	0	2	0
		Ž	433	0	27	173	233
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	43	0	13	16	14
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	65	0	2	28	35
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	136	0	6	83	47
C61	Prostata Prostate	M	464	0	1	124	339
		Ž	-	-	-	-	-
C62	Modo Testis	M	5	0	1	2	2
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	125	0	4	57	64
		Ž	60	0	2	21	37
C67	Sečni mehur Bladder	M	143	0	0	52	91
		Ž	77	0	1	25	51
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	108	2	17	61	28
		Ž	69	3	8	33	25
C73	Ščitnica Thyroid gland	M	6	0	1	2	3
		Ž	6	0	0	3	3
C81	Hodgkinov limfom Hodgkin's lymphoma	M	2	0	0	1	1
		Ž	3	0	0	1	2
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	74	0	3	30	41
		Ž	83	0	0	36	47
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	68	0	0	30	38
		Ž	51	0	1	16	34
C91-C95	Levkemije Leukaemias	M	127	1	7	53	66
		Ž	96	2	1	32	61

Tabela 8: Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2013–2017.

Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2013–2017 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje s 95 % intervalom zaupanja		Pet-letno preživetje s 95 % intervalom zaupanja	
			One-year survival with 95% confidence interval		Five-year survival with 95% confidence interval	
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	74,0	73,6–74,4	58,4	57,8–58,9
		M	72,4	71,9–73,0	56,7	56,0–57,4
		Ž	75,9	75,3–76,4	60,4	59,6–61,2
C00–C14	Usta in žrelo Mouth and pharynx	M	72,1	69,6–74,6	44,0	40,9–47,2
		Ž	84,7	81,0–88,6	66,1	59,9–73,0
C15	Požiralnik Oesophagus	M	39,1	34,2–44,8	10,0	6,9–14,4
		Ž	38,7	29,5–51,0	17,2	10,5–28,2
C16	Želodec Stomach	M	52,0	49,3–54,8	30,3	27,5–33,5
		Ž	49,0	45,6–52,7	30,5	26,9–34,5
C18	Debelo črevo Colon	M	78,9	77,1–80,8	61,5	58,7–64,5
		Ž	76,2	74,1–78,3	62,1	59,1–65,2
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	84,4	82,6–86,3	64,3	61,2–67,5
		Ž	79,1	76,4–81,9	59,2	55,2–63,4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	33,0	29,8–36,6	10,7	8,4–13,7
		Ž	32,3	27,3–38,3	10,7	7,4–15,5
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	35,9	31,5–40,9	14,1	10,8–18,5
		Ž	31,1	27,3–35,5	14,5	11,3–18,5
C25	Trebšna slinavka Pancreas	M	24,8	22,2–27,8	6,0	4,4–8,1
		Ž	24,9	22,2–27,9	6,9	5,3–9,1
C32	Grlo Larynx	M	85,9	82,3–89,5	60,3	54,4–66,8
		Ž	*	*	*	*
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	41,8	40,3–43,3	16,0	14,7–17,3
		Ž	50,5	48,5–52,5	23,4	21,5–25,5
C43	Malignni melanom kože Malignant melanoma of skin	M	97,6	96,4–98,8	91,6	88,7–94,6
		Ž	98,0	96,9–99,1	91,4	88,6–94,4
C44	Druge maligne neoplazme kože Skin, other malignomas	M	**	**	**	**
		Ž	**	**	**	**
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	79,1	72,6–86,3	56,7	47,8–67,2
		Ž	79,7	74,3–85,6	53,0	45,8–61,5
C50	Dojka Breast	M	*	*	*	*
		Ž	96,8	96,3–97,4	88,0	86,6–89,3
C53	Maternični vrat Cervix uteri	M	–	–	–	–
		Ž	85,8	82,8–88,9	67,8	63,2–72,7
C54	Maternično telo Corpus uteri	M	–	–	–	–
		Ž	91,5	90,0–93,0	80,3	77,7–83,0
C56	Jajčnik Ovary	M	–	–	–	–
		Ž	74,6	71,5–77,8	40,0	36,3–44,2
C61	Prostata Prostate	M	97,3	96,8–97,8	93,3	92,0–94,6
		Ž	–	–	–	–
C62	Modo Testis	M	99,1	98,3–99,9	97,3	95,6–99,0
		Ž	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	78,3	75,9–80,8	65,7	62,1–69,4
		Ž	77,0	73,7–80,5	67,3	62,7–72,2
C67	Sečni mehur Bladder	M	74,0	71,4–76,7	53,9	49,9–58,3
		Ž	70,4	66,1–74,9	49,1	43,1–56,0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	47,8	43,7–52,4	20,5	17,1–24,6
		Ž	45,7	40,8–51,2	19,6	15,7–24,4
C73	Ščitnica Thyroid gland	M	95,1	91,9–98,4	90,8	85,4–96,5
		Ž	96,9	95,5–98,3	95,8	93,4–98,3
C81	Hodgkinov limfom Hodgkin's lymphoma	M	90,8	86,0–96,0	83,5	76,5–91,1
		Ž	92,8	88,1–97,7	88,4	81,2–96,3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	75,8	73,1–78,6	65,7	61,9–69,8
		Ž	76,9	74,2–79,7	62,1	58,3–66,1
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	72,3	67,6–77,4	42,3	35,7–50,1
		Ž	75,4	70,4–80,7	44,6	37,7–52,8
C91–C95	Levkemije Leukaemias	M	67,8	64,7–71,1	51,8	47,7–56,1
		Ž	68,4	64,9–72,2	49,8	44,8–55,3

* Število v analizo vključenih bolnikov je manjše od 15 povprečno letno / Average number of patients included in the analysis is less than 15 yearly

** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo

Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population

Tabela 9a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL).

Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given).

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemsko terapijo Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število (od tega OIL) Number (IOL only)	%**
C00-C96	Vse lokacije / All sites	14946	12128	81,1	9487	63,5	4294	28,7	3180 (2937)	21,3
C00-C14	Usta in žrelo Mouth and pharynx	350	325	92,9	186	53,1	25	7,1	257 (256)	73,4
C15	Požiralnik Oesophagus	88	49	55,7	16	18,2	31	35,2	38 (37)	43,2
C16	Želodec Stomach	423	263	62,2	193	45,6	127	30,0	68 (67)	16,1
C18	Debelo črevo Colon	782	671	85,8	643	82,2	188	24,0	10 (10)	-
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	536	445	83,0	378	70,5	197	36,8	213 (211)	39,7
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	260	101	38,8	41	15,8	56	21,5	1 (0)	-
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	194	88	45,4	66	34,0	28	14,4	5 (3)	-
C25	Trebušna slinavka Pancreas	406	167	41,1	91	22,4	108	26,6	10 (9)	-
C32	Grlo Larynx	94	89	94,7	44	46,8	6	-	69 (68)	73,4
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1451	1022	70,4	332	22,9	524	36,1	556 (512)	38,3
C43	Maligni melanom kože Malignant melanoma of skin	578	575	99,5	574	99,3	12	-	32 (32)	5,5
C44	Druge maligne neoplazme kože Skin, other malignomas	3156	3098	98,2	2990	94,7	23	0,7	105 (105)	3,3
C48-C49	Veživo in mehko tkivo Connective and soft tissue	71	62	87,3	52	73,2	21	29,6	20 (19)	28,2
C50	Dojka Breast	1403	1358	96,8	1202	85,7	1217	86,7	860 (692)	61,3
C53	Maternični vrat Cervix uteri	86	79	91,9	57	66,3	3	-	46 (45)	53,5
C54	Maternično telo Corpus uteri	350	330	94,3	311	88,9	52	14,9	122 (122)	34,9
C56	Jajčnik Ovary	157	127	80,9	111	70,7	101	64,3	4 (3)	-
C61	Prostata Prostate	1590	1105	69,5	760	47,8	438	27,5	202 (199)	12,7
C62	Modo Testis	125	125	100	125	100,0	69	55,2	1 (1)	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	402	321	79,9	295	73,4	32	8,0	19 (16)	4,7
C67	Sečni mehur Bladder	356	328	92,1	324	91,0	47	13,2	20 (19)	5,6
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	201	164	81,6	160	79,6	96	47,8	113 (110)	56,2
C73	Ščitnica Thyroid gland	211	207	98,1	199	94,3	202	95,7	125 (125)	59,2
C81	Hodgkinov limfom Hodgkin's lymphoma	57	52	91,2	0	-	50	87,7	29 (29)	50,9
C82-C85	ne-Hodgkinovi limfomi non-Hodgkin's lymphoma	390	276	70,8	51	13,1	211	54,1	94 (94)	24,1
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	141	119	84,4	5	-	112	79,4	18 (16)	12,8
C91-C95	Levkemije Leukaemias	329	171	52,0	2	-	167	50,8	14 (14)	-

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko terapijo ali obsevanje)
Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15
Percentages are not calculated for less than 15 cases

Tabela 9b:

Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji bolnih leta 2017, ki so bili v okviru prvega zdravljenja operirani*, po bolnici posega.

Table 9b:

Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery during their first treatment* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Splošna bolnišnica Trbovlje	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00-C96	Vse lokacije All sites	14946	9487	773	298	202	2403	1361	1592	349	345	482	89	553	33	862	145
C00-C14	Usta in žrelo Mouth and pharynx	350	186	3	1	0	103	0	70	3	2	3	0	0	0	0	1
C15	Požiralnik Oesophagus	88	16	0	0	0	14	0	1	0	0	0	0	0	0	1	0
C16	Želodec Stomach	423	193	9	5	4	95	11	51	8	1	0	0	4	0	4	1
C18	Debelo črevo Colon	782	643	52	53	26	182	44	87	31	26	36	20	35	17	29	5
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	536	378	21	20	23	93	70	47	22	3	20	9	19	6	23	2
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	260	41	0	0	0	22	0	19	0	0	0	0	0	0	0	0
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	194	66	1	0	1	35	0	21	1	3	2	0	2	0	0	0
C25	Trebušna slinavka Pancreas	406	91	0	0	1	60	0	28	0	0	0	0	0	0	0	2
C32	Grlo Larynx	94	44	0	0	0	33	0	11	0	0	0	0	0	0	0	0
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1451	332	1	0	0	112	0	65	0	0	0	0	0	0	145	9
C43	Maligni melanom kože Malignant melanoma of skin	578	574	63	28	18	133	33	82	13	21	35	2	22	2	80	42
C44	Druge maligne neoplazme kože Skin, other malignomas	3156	2990	363	166	40	520	36	572	185	113	251	56	129	1	544	14
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	71	52	2	1	1	8	27	1	4	2	2	1	1	0	2	0
C50	Dojka Breast	1403	1202	25	0	36	0	887	150	2	68	0	0	31	0	1	2
C53	Maternični vrat Cervix uteri	86	57	2	3	1	33	5	4	1	0	1	0	1	0	0	6
C54	Maternično telo Corpus uteri	350	311	18	9	7	134	33	50	17	6	3	0	16	4	0	14
C56	Jajčnik Ovary	157	111	8	3	2	44	22	20	2	1	1	0	4	0	0	4
C61	Prostata Prostate	1590	760	140	0	16	135	0	90	33	55	42	0	221	0	18	10
C62	Modo Testis	125	125	8	0	5	69	0	16	2	5	9	0	5	0	0	6
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	402	295	17	0	5	112	1	52	10	17	38	0	35	0	1	7
C67	Sečni mehur Bladder	356	324	18	0	11	147	0	55	10	18	31	0	25	0	0	9
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	201	160	2	0	0	117	0	36	0	0	0	0	0	0	0	5
C73	Ščitnica Thyroid gland	211	199	11	0	0	26	145	10	0	0	0	0	0	0	7	0
C81	Hodgkinov limfom Hodgkin's lymphoma	57	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C82-C85	ne-Hodgkinovi limfomi non-Hodgkin's lymphoma	390	51	1	2	0	19	8	10	3	1	4	0	0	1	2	0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	141	5	0	0	0	1	0	4	0	0	0	0	0	0	0	0
C91-C95	Levkemije Leukaemias	329	2	0	0	0	1	0	1	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

Less than 30 patients were treated by surgery in individual institution

Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po bolnici zdravljenja.
 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by systemic therapy during their first treatment* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00-C96	Vse lokacije All sites	14946	4294	122	145	28	440	2567	712	34	96	24	84	22	20
C00-C14	Usta in žrelo Mouth and pharynx	350	25	0	1	0	0	24	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	88	31	0	0	0	1	26	3	0	0	0	0	0	1
C16	Želodec Stomach	423	127	3	0	0	14	73	33	0	4	0	0	0	0
C18	Debelo črevo Colon	782	188	11	0	0	9	110	45	0	4	0	9	0	0
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	536	197	2	0	0	2	177	15	0	0	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	260	56	1	0	0	38	2	12	0	0	0	1	0	2
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	194	28	0	0	0	13	3	12	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	406	108	3	0	0	42	29	27	0	4	0	3	0	0
C32	Grlo Larynx	94	6	0	0	0	0	6	0	0	0	0	0	0	0
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1451	524	0	138	0	0	264	120	0	0	0	0	0	2
C43	Maligni melanom kože Malignant melanoma of skin	578	12	0	0	0	0	12	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	3156	23	1	0	0	4	2	14	0	0	0	0	0	2
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	71	21	0	0	0	1	18	2	0	0	0	0	0	0
C50	Dojka Breast	1403	1217	41	0	19	0	850	237	0	43	0	23	1	3
C53	Maternični vrat Cervix uteri	86	3	0	0	0	0	3	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	350	52	0	0	0	2	41	8	0	1	0	0	0	0
C56	Jajčnik Ovary	157	101	0	0	0	0	79	22	0	0	0	0	0	0
C61	Prostata Prostate	1590	438	30	0	9	51	164	71	13	32	14	36	15	3
C62	Modo Testis	125	69	0	0	0	1	68	0	0	0	0	0	0	0
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	402	32	0	0	0	1	24	6	0	1	0	0	0	0
C67	Sečni mehur Bladder	356	47	0	0	0	1	34	6	3	2	0	1	0	0
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	201	96	0	0	0	4	92	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	211	202	11	0	0	25	150	10	0	0	0	0	6	0
C81	Hodgkinov limfom Hodgkin's lymphoma	57	50	0	0	0	6	44	0	0	0	0	0	0	0
C82-C85	ne-Hodgkinovi limfomi non-Hodgkin's lymphoma	390	211	2	1	0	18	180	6	1	1	0	2	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	141	112	12	0	0	60	0	12	9	2	9	5	0	3
C91-C95	Levkemije Leukaemias	329	167	4	0	0	115	6	26	7	2	1	3	0	3

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat
 Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov
 Less than 10 patients were treated in individual institution

Breme najpogostejših rakov


Cancer Fact Sheets

Vsi raki / All cancer sites (C00–C96)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	7928	6708	14636
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	100,0	100,0	100,0
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	121,9	126,6	124,1
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	38,1	28,6	33,2
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	775,2	644,9	709,5
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	401,9	300,6	343,4
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,88*	2,08*	1,98*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,21	0,98*	0,43
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	3456	2704	6160
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	100	100	100
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	15,8	9,5	12,6
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	337,9	260	298,6
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	157,6	92,1	120,1
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	1,01*	0,78*	0,92*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,76*	-0,74*	-1,25*
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	57766	66521	124287
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	5630,4	6395,1	6015,4
1-letna prevalenca / 1-year prevalence	6605	5992	12597
5-letna prevalenca / 5-year prevalence	25742	23732	49474

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Prostata / Prostate (C61)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men
Število novih primerov v enem letu / Number of new cases per year	1613
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	20,3
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	1.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	24,8
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	10,3
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	157,7
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	78,6
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,97*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,23
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)	
Število smrti v enem letu / Number of deaths per year	403
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	11,7
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	1,1
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	39,4
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	15,3
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	2,09*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,61*
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)	
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	14143
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	1378,5
1-letna prevalenca / 1-year prevalence	1510
5-letna prevalenca / 5-year prevalence	6893

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Pljuča in sapnik / Lung and trachea (C33, C34)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	927	495	1422
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	11,7	7,4	9,7
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	3.	4.	3.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	14,3	9,3	12,1
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	5,7	2,7	4,1
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	90,6	47,6	68,9
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	46,0	21,7	32,8
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	0,75	5,94*	2,41*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,44*	4,83*	0,68
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	798	389	1187
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	23,1	14,4	19,3
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	4,7	1,9	3,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	78,0	37,4	57,5
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	38,4	15,6	25,9
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	0,14	4,15*	1,40*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,14*	2,87*	-0,41
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	2033	1402	3435
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	198,2	134,8	166,3
1-letna prevalenca / 1-year prevalence	515	389	904
5-letna prevalenca / 5-year prevalence	1281	967	2248

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Dojka / Breast (C50)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Ženske / Women
Število novih primerov v enem letu / Number of new cases per year	1345
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	20,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	2.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	25,4
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	7,6
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	129,3
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	70,0
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,00*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,32*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)	
Število smrti v enem letu / Number of deaths per year	408
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	15,1
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	1,6
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	39,2
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	14,5
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,71
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,38*
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)	
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	17869
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	1717,9
1-letna prevalenca / 1-year prevalence	1348
5-letna prevalenca / 5-year prevalence	5959

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Debelo črevo in danka / Colon and rectum (C18–C20)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	825	567	1393
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	10,4	8,5	9,5
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	4.	3.	4.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	12,7	10,7	11,8
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	4,7	2,5	3,6
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	80,7	54,5	67,5
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	40,3	21,6	30,1
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-1,98*	-2,26*	-2,09*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-4,23*	-3,85*	-3,94*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	439	321	760
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	12,7	11,9	12,3
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	2,04	0,94	1,46
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	42,9	30,9	36,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	19,5	9,6	13,9
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,31	-1,26	-0,74
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,04*	-3,26*	-3,02*
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	6676	5151	11827
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	650,7	495,2	572,4
1-letna prevalenca / 1-year prevalence	659	444	1103
5-letna prevalenca / 5-year prevalence	2694	1805	4499

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Koža, razen melanoma / Skin, non-melanoma (C44)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	1427	1411	2838
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	18,0	21,0	19,4
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	2.	1.	1.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	21,9	26,6	24,1
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	7,3	5,8	6,5
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	139,5	135,7	137,6
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	67,7	54,3	59,5
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	5,27*	4,32*	4,79*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	2,81*	3,35*	3,15*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	15	19	34
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	0,4	0,7	0,6
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	0,04	0,01	0,02
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	1,5	1,8	1,7
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	0,6	0,3	0,4
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	1,37	0,91	0,84
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,07	-2,90	-4,06
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	14257	15681	29938
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	1389,6	1507,5	1449,0
1-letna prevalenca / 1-year prevalence	1519	1584	3103
5-letna prevalenca / 5-year prevalence	6381	6447	12828

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Kožni melanom / Malignant melanoma of skin (C43)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	295	261	556
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	3,7	3,9	3,8
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	6.	6.	6.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	4,5	4,9	4,7
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	1,8	1,5	1,6
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	28,9	25,1	26,9
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	16,6	14,5	15,3
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	3,90*	0,97	2,46*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,93*	-0,31	0,75
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	67	54	122
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,0	2,0	2,0
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	0,4	0,2	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	6,6	5,2	5,9
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	3,3	2,1	2,7
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	2,15	-0,35	0,93
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,76	-2,48	-1,57
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	3013	3675	6688
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	293,7	353,3	323,7
1-letna prevalenca / 1-year prevalence	291	271	562
5-letna prevalenca / 5-year prevalence	1290	1180	2470

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Glava in vrat / Head and neck (C00–C14, C30–C32)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	371	99	470
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	4,7	1,5	3,2
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.	14.	7.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	5,7	1,9	4,0
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	2,5	0,6	1,5
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	36,3	9,5	22,8
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	20,3	4,9	12,4
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-0,72	2,45	-0,08
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,47*	1,58	-1,60*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	180	36	216
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	5,2	1,3	3,5
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	1,2	0,2	0,7
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	17,6	3,5	10,5
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	9,4	1,5	5,2
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-1,52*	0,78	-1,10
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,48*	0,05	-2,87*
PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	2662	928	3590
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	259,5	89,2	173,8
1-letna prevalenca / 1-year prevalence	322	88	410
5-letna prevalenca / 5-year prevalence	1107	358	1465

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Maternično telo / Corpus uteri (C54)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Ženske / Women
Število novih primerov v enem letu / Number of new cases per year	347
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	5,2
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	6,5
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	2,0
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	33,3
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	15,8
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,81*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,52*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)	
Število smrti v enem letu / Number of deaths per year	61
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,3
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	0,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	5,9
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	2,0
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	3,17
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	2,01
PREVALENCIA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)	
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	4784
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	459,9
1-letna prevalenca / 1-year prevalence	325
5-letna prevalenca / 5-year prevalence	1434

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrljivost Mortality Slovenija 1985–2017




Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)


INCIDENCA (povprečje v obdobju 2013–2017) / INCIDENCE (average 2013–2017)	Moški / Men	Ženske / Women	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	215	202	417
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	2,7	3,0	2,8
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	10.	7.	9.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%)	3,3	3,8	3,5
Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%)	1,2	1,0	1,1
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	21,0	19,5	20,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W)	11,5	8,7	10,0
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	5,29*	4,57*	4,93*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	2,92*	3,57*	3,23*
UMRLJIVOST (povprečje v obdobju 2013–2017) / MORTALITY (average 2013–2017)			
Število smrti v enem letu / Number of deaths per year	83	86	169
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,4	3,2	2,7
Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%)	0,4	0,2	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	8,1	8,2	8,2
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W)	3,8	2,4	3,0
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	4,82*	5,47*	5,11*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,75	3,72	2,71
PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017)			
Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence)	1641	1648	3289
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017	159,9	158,4	159,2
1-letna prevalenca / 1-year prevalence	141	165	306
5-letna prevalenca / 5-year prevalence	699	660	1359

* Statistično značilno / Statistically significant

Incidenca Incidence Slovenija 1961–2017



Umrlijivost Mortality Slovenija 1985–2017



Definicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA:
<http://www.slora.si/definicije-kazalnikov-in-metod>.

- Incidenca** Število vseh na novo ugotovljenih primerov raka v točno določeni populaciji v enem koledarskem letu.
- Umrljivost** Število vseh umrlih za določeno boleznijo v točno določeni populaciji v enem koledarskem letu.
- Prevalenca** Število vseh bolnikov z določeno boleznijo, ki so bili živi na izbrani datum (ponavadi zadnji dan v letu). Glede na čas, kdaj so zboleli, ločimo:
- Celotna prevalenca upošteva vse bolnike z rakom, ne glede na to kdaj so zboleli.
 - Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v točno določenem obdobju pred datumom izračuna. Na primer, v enoletni delni prevalenci so vključeni bolniki, ki so zboleli leto pred datumom izračuna ter so na ta datum še živi.
- Preživetje** Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V poročilu podajamo čisto preživetje izračunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proučevanega raka (hipotetičen primer, v katerem ne umirajo za drugimi vzroki smrti).
- Groba stopnja** Incidenca ali umrljivost preračunani na velikost opazovane populacije. Običajno je izražena na 100.000 prebivalcev.
- Starostno standardizirana stopnja** Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, če bi bila starostna struktura te populacije enaka kot je v standardni populaciji. Uporabljene so tri standardne populacije: svetovno (Segi 1961), evropsko (Doll 1976) in slovensko standardno populacijo (Popis 2002).
- Kumulativna stopnja** Kumulativna incidenčna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje.
- Kumulativno tveganje** Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), če ne umre prej zaradi drugih vzrokov.
- Ocena incidence** Ocena števila novih primerov za tekoče koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vključeni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo.

Definitions of indices and methods are explained in detail on web portal SLORA:
<http://www.slora.si/en/definicije-kazalnikov-in-metod>.

Incidence Number of all newly diagnosed cancer cases that develop in a defined population in one calendar year.

Mortality Number of all patients who died because of certain disease in a defined population in one calendar year.

Prevalence Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnose we distinguish:

- Lifetime prevalence is defined as the number of all persons ever diagnosed with cancer and being alive at specific time date.
- Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation.

Survival In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients' survival from cancer only (all other causes of death excluded).

Crude rate Incidence or mortality calculated per observed population, usually expressed per 100.000 population.

Age-standardized rate Age-standardization tells the crude rate in observed population in case if it's age structure is the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002).

Cumulative rate The cumulative incidence or mortality rate is a special form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk.

Cumulative risk Cumulative risk is expressed in percentages and interpreted as the risk an individual would have of developing the disease in question during a certain age period (e.g. up to the age of 74), if no other causes of death were in operation.

Estimation of incidence Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years.

